

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

USIN: U8/833,610

B-1

FICN 00/000 000




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :	A1	(11) International Publication Number: WO 96/10086
C12N 15/54, 9/10, 5/10, C12P 19/18 // (C12N 9/10, C12R 1:36)		(43) International Publication Date: 4 April 1996 (04.04.96)
(21) International Application Number: PCT/US95/12317		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
(22) International Filing Date: 25 September 1995 (25.09.95)		
(30) Priority Data: 08/312,387 26 September 1994 (26.09.94) US		
(71) Applicant: THE ROCKEFELLER UNIVERSITY [US/US]; 1230 York Avenue, New York, NY 10021-6399 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(72) Inventor: GOTSCHLICH, Emil, C.; 500 East 63rd Street, New York, NY 10021 (US).		
(74) Agents: FEHLNER, Paul, F. et al.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).		

(54) Title: GLYCOSYLTRANSFERASES FOR BIOSYNTHESIS OF OLIGOSACCHARIDES, AND GENES ENCODING THEM

LOS Locus



(57) Abstract

The present invention is directed to nucleic acids encoding glycosyltransferases, the proteins encoded thereby, and to methods for synthesizing oligosaccharides using the glycosyltransferases of the invention. In a specific embodiment, a glycosyltransferase locus of *Neisseria gonorrhoeae* containing five open reading frames for five different glycosyltransferases. The functionally active glycosyltransferases of the invention are characterized by catalyzing reactions such as adding Gal $\beta 1 \rightarrow 4$ to GlcNAc or Glc; adding GalNAc or GlcNAc $\beta 1 \rightarrow 3$ to Gal; and adding Gal $\alpha 1 \rightarrow 4$ to Gal. The glycosyltransferases of the invention are particularly suited to the syntheses of the oligosaccharides Gal $\beta 1 \rightarrow 4$ GlcNAc $\beta 1 \rightarrow 3$ Gal $\beta 1 \rightarrow 4$ Glc (a mimic of lacto-N-neotetraose), GalNAc $\beta 1 \rightarrow 3$ Gal $\beta 1 \rightarrow 4$ GlcNAc $\beta 1 \rightarrow 3$ Gal $\beta 1 \rightarrow 4$ Glc $\beta 1 \rightarrow 4$ (a mimic ganglioside), and Gal $\alpha 1 \rightarrow 4$ Gal $\beta 1 \rightarrow 4$ Glc $\beta 1 \rightarrow 4$ Hep \rightarrow R (a mimic of the saccharide portion of globoglycolipids).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

GLYCOSYLTRANSFERASES FOR BIOSYNTHESIS OF OLIGOSACCHARIDES, AND GENES ENCODING THEM

The research leading to the present invention was supported in part with funds from grant number AI-10615 from the Public Health Service. Accordingly, the

5 Government may have certain rights in the invention.

FIELD OF THE INVENTION

The present invention relates to glycosyltransferases useful for biosynthesis of oligosaccharides, genes encoding such glycosyltransferases and recombinant methods of producing the enzymes, and the oligosaccharides produced thereby.

10

BACKGROUND OF THE INVENTION

Neisseria and Lipo-oligosaccharide (LOS)

While *Neisseria* species commonly colonize many mammalian hosts, human beings are the only species subject to invasive disease by members of this species. *Neisseria meningitidis* is the etiologic agent for septicemia and meningitis that may 15 occur in epidemic form. *Neisseria gonorrhoeae* is the causative agent of gonorrhea and its manifold complications. These organisms, particularly the gonococcus, have proved remarkably adept at varying the antigenic array of their surface-exposed molecules, notably their adhesive pili and opacity-related (opa) proteins. The genetic mechanisms for the variation of pilus (Meyer et al., 1982, 20 Cell 30:45; Haas and Meyer, 1986, Cell 44:107; Koomey et al., 1987, Genetics 117:391; Swanson and Koomey, 1989, American Society for Microbiology, Washington, 743-761) and opa protein (Stern et al., 1986, Cell 47:61; Meyer et al., 1990, Ann. Rev. Microbiol. 44:451; Bhat et al., 1991, Molec. Microbiol. 5:1889) expression are in the main well understood. Like other Gram-negative 25 bacteria the *Neisseria* spp. carry LPS in the external leaflet of their outer membranes (Johnston and Gotschlich, 1974, J. Bacteriol. 119:250). In contrast to the high molecular weight LPS molecules with repeating O-chains seen in many enteric bacteria, the LPS of *Neisseria* spp. is of modest size and therefore is often

referred to as lipooligosaccharide or LOS. Although the molecular size of the LOS is similar to that seen in rough LPS mutants of *Salmonella* ssp., this substance has considerable antigenic diversity. In the case of the meningococcus, a serological typing scheme has been developed that separates strains into 12 immunotypes (Zollinger and Mandrell, 1977, Infect. Immun. 18:424; Zollinger and Mandrell, 1980, Infect. Immun. 28:451). A remarkably complete understanding of the structure of meningococcal LPS (recently reviewed (Verheul et al., 1993, Microbiol. Rev. 57:34) has resulted from the studies of Jennings and his colleagues (Jennings et al., 1983, Carbohydr. Res. 121:233; Michon et al., 1990, J. Biol. Chem. 265:7243; Gamian et al., 1992, J. Biol. Chem. 267:922; Pavliak et al., 1993, J. Biol. Chem. 268:14146). In the case of *Neisseria gonorrhoeae*, antigenic variability is so pronounced that a serological classification scheme has proved elusive. In part this is due to the heterogeneity of LOS synthesized by a particular strain; LOS preparations frequently contain several closely spaced bands by SDS-PAGE (Mandrell et al., 1986, Infect. Immun. 54:63). Further, studies using monoclonal antibodies indicate that gonococci are able to change the serological characteristics of the LOS they express and that this antigenic variation occurs at a frequency of 10^{-2} to 10^{-3} , indicating that some genetic mechanism must exist to achieve these high frequency variations (Schneider et al., 1988, Infect. Immun. 56:942; Apicella et al., 1987, Infect. Immun. 55:1755). Because of the molecular heterogeneity and antigenic variation of the LOS produced by gonococci the determination of the structural chemistry of this antigen has proved to be a difficult problem, and definitive information based on very sophisticated analyses has only recently become available (Yamasaki et al., 1991, Biochemistry 30:10566; Kerwood et al., 1992, Biochemistry 31:12760; John et al., 1991, J. Biol. Chem. 266:19303; Gibson et al., 1993, J. Bacteriol. 175:2702). These are summarized in Figure 1. Of particular interest is the presence of the tetrasaccharide Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc β 1 \rightarrow 4, which is a perfect mimic of lacto-N-neotetraose of the sphingolipid paragloboside (Mandrell et al., 1988, J. Exp. Med. 168:107; Tsai and Civin, 1991, Infect. Immun. 59:3604). In LOS this tetrasaccharide frequently bears an additional N-acetyl

galactosamine residue ($\text{GalNAc}\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 4\text{GlcNAc}\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 4\text{Glc}\beta 1\rightarrow 4$), and then mimics gangliosides. In some strains of gonococci an alternative side chain is found which has the structure $\text{Gal}\alpha 1\rightarrow 4\text{Gal}\beta 1\rightarrow 4\text{Glc}\beta 1\rightarrow 4\text{Hep}\rightarrow \text{R}$ (John et al., 1991, *J. Biol. Chem.* 266:19303). This is a mimic of the saccharide portion of 5 globo-glycolipids (Mandrell, 1992, *Infect. Immun.* 60:3017), and is the structure characteristically found in *Neisseria meningitidis* immunotype L1.

The LOS molecules have a number of biological activities. They are potent endotoxic molecules believed to be the toxin responsible for adrenal cortical necrosis seen in severe meningococcal disease. They serve as the target antigen 10 for much of the bactericidal activity present in normal or convalescent human sera (Rice et al., 1980, *J. Immunol.* 124:2105). Gonococci possess a very unusual sialyl transferase activity which is able to use externally supplied CMP-NANA and add N-acetyl neuraminic acid to the LOS on the surface of the organism (Nairn et al., 1988, *J. Gen. Microbiol.* 134:3295; Parsons et al., 1989, *Microb. Pathog.* 7:63; Mandrell et al., 1990, *J. Exp. Med.* 171:1649). Group B and C meningococci, have the capacity to synthesize CMP-NANA, and frequently sialylate their LOS without requiring exogenous CMP-NANA (Mandrell et al., 1991, *J. Bacteriol.* 173:2823). In *Neisseria meningitidis* strain 6275 immunotype L3, the sialic acid unit is linked $\alpha 2\rightarrow 3$ to the terminal Gal residue of the lacto-N-20 neotetraose (Yamasaki et al., 1993, *J. Bacteriol.* 175:4565). The levels of CMP-NANA found in various host environments is sufficient to support this reaction (Apicella et al., 1990, *J. Infect. Dis.* 162:506). The sialylation of the LOS causes gonococci to become resistant to the antibody-complement dependent bactericidal effect of serum (Parsons et al., 1989, *Microb. Pathog.* 7:63). The resistance is 25 not only to the bactericidal effect mediated by antibodies to LOS, but to other surface antigens as well (Wetzler et al., 1992, *Infect. Immun.* 60:39). van Putten has demonstrated that exposure of gonococci to CMP-NANA markedly reduces their ability to invade epithelial cells in tissue culture (Van Putten, 1993, *EMBO J.* 12:4043). These findings strongly suggest that the ability of gonococci to vary the

chemical nature of the LOS provides them with the ability to cope with different host environments (Mandrell and Apicella, 1993, *Immunobiology* 187:382).

Perhaps most telling, it has been found that LOS variation is selected *in vivo* in infections of human beings. A well characterized gonococcal laboratory strain 5 **MS11_{mk}** variant A was used to inoculate volunteers (Swanson et al., 1988, *J. Exp. Med.* 168:2121). In the two infected individuals over a period of 4 to 6 days the population of gonococci recovered in their urine increasingly shifted to two variants that expressed antigenically different LOS (Schneider et al., 1991, *J. Exp. Med.* 174:1601). A structural analysis revealed that the inoculated variant A 10 produced a truncated LOS containing only the β -lactosyl group linked to Hep1, while one of the new variants (variant C) produced a complete LOS (Kerwood et al., 1992, *Biochemistry* 31:12760). This suggests that the addition of the additional sugars GalNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3 is likely to be under control of a phase variation mechanism.

15 Little information on the genetics of LOS synthesis in *Neisseria* is available. A major advance has been the creation (Dudas and Apicella, 1988, *Infect. Immun.* 56:499) and biochemical characterization (John et al., 1991, *J. Biol. Chem.* 266:19303) of five pyocin mutants of gonococcal strain 1291, dubbed 1291a-e. Immunological and biochemical data have shown that 1291a, 1291c, 1291d and 20 1291e produce LOS with sequential shortening of the lacto-N-neotetraose chain, with mutant 1291e lacking the glucose substitution on the heptose. Mutant 1291b synthesizes the alternative LOS structure Gal α 1 \rightarrow 4Gal β 1 \rightarrow 4Glc (see Figure 1). Only the genetic basis of the 1291e mutant is now defined. It is a mutation of phosphoglucomutase (*pgm*), which precludes the synthesis of UDP-glucose, and 25 hence the addition of the first residue of the lacto-N-neotetraose unit (Zhou et al., 1994, *J. Biol. Chem.* 269:11162; Sandlin and Stein, 1994, *J. Bacteriol.* 176:2930). It also has been shown that *galE* mutants of meningococcus or gonococcus produce truncated LOS in keeping with the inability to synthesize

UDP-galactose (Robertson et al., 1993, Molec. Microbiol. 8:891; Jennings et al., 1993, Molec. Microbiol. 10:361).

Biosynthesis of Oligosaccharides

Oligosaccharides are polymers of varying number of residues, linkages, and 5 subunits. The basic subunit is a carbohydrate monosaccharide or sugar, such as mannose, glucose, galactose, N-acetylglucosamine, N-acetylgalactosamine, and the like. The number of different possible stereoisomeric oligosaccharide chains is enormous.

10 Oligosaccharides and polysaccharides play an important role in protein function and activity, by serving as half-life modulators, and, in some instances, by providing structure. As pointed out above, oligosaccharides are critical to the antigenic variability, and hence immune evasion, of *Neisseria*, especially gonococcus.

15 Numerous classical techniques for the synthesis of carbohydrates have been developed, but these techniques suffer the difficulty of requiring selective protection and deprotection. Organic synthesis of oligosaccharides is further hampered by the lability of many glycosidic bonds, difficulties in achieving regio-selective sugar coupling, and generally low synthetic yields. In short, unlike the experience with peptide synthesis, traditional synthetic organic chemistry cannot 20 provide for quantitative, reliable synthesis of even fairly simple oligosaccharides.

Recent advances in oligosaccharide synthesis have occurred with the isolation of glycosyltransferases. These enzymes can be used *in vitro* to prepare 25 oligosaccharides and polysaccharides (see, e.g., Roth, U.S. Patent No. 5,180,674, issued January 19, 1993). The advantage of biosynthesis with glycosyltransferases is that the glycosidic linkages formed by enzymes are highly stereo and regio-specific. However, each enzyme catalyzes linkage of specific sugar residues to other specific acceptor molecules, e.g., an oligosaccharide or lipid. Thus,

synthesis of a desired oligosaccharide may be limited by the availability of glycosyltransferases (see, Roth, International Patent Publication No. WO 93/13198, published July 8, 1993).

Another drawback of biosynthesis is that the glycosyltransferases themselves are

5 usually present in fairly low quantities in cells. It is difficult to obtain enough of the enzyme to be commercially practicable.

Thus, there is a great need in the art for glycosyltransferases. There is a further need for genes encoding such glycosyltransferases, to provide an unlimited source of glycosyltransferases through recombinant technology.

10 The citation of any reference herein should not be construed as an admission that such reference is available as prior art to the instant invention.

SUMMARY OF THE INVENTION

The present invention is directed to nucleic acids encoding glycosyltransferases, the proteins encoded thereby, and to methods for synthesizing oligosaccharides

15 using the glycosyltransferases of the invention. Accordingly, in one aspect, the invention is directed to a purified nucleic acid that is hybridizable under moderately stringent conditions to a nucleic acid corresponding to the LOS locus of *Neisseria*, e.g., a nucleic acid having a nucleotide sequence corresponding to or complementary to the nucleotide sequence shown in Figure 2 (SEQ ID NO:1).

20 Preferably, the nucleic acid of the invention is hybridizable to a portion of the coding sequence for a gene of the LOS locus, i.e., a portion of the nucleotide sequence shown in Figure 2 (SEQ ID NO:1) that encodes a functionally active glycosyltransferase.

In specific embodiments, the invention relates to a nucleic acid that has a

25 nucleotide sequence corresponding to or complementary to a portion of the

nucleotide sequence shown in Figure 2 (SEQ ID NO:1) that encodes a functionally active glycosyltransferase. In a further aspect, the nucleic acid encodes a functionally active glycosyltransferase. In a specific embodiment, the invention is directed to a nucleic acid that has a nucleotide sequence corresponding to or 5 complementary to the nucleotide sequence shown in Figure 2 (SEQ ID NO:1).

The functionally active glycosyltransferases of the invention are characterized by catalyzing a reaction selected from the group consisting of:

adding Gal $\beta 1 \rightarrow 4$ to GlcNAc or Glc;

adding GalNAc or GlcNAc $\beta 1 \rightarrow 3$ to Gal; and
10 adding Gal $\alpha 1 \rightarrow 4$ to Gal.

Most preferably, the claimed nucleic acid encodes a functionally active glycosyltransferase. However, nucleic acids of the invention include oligonucleotides useful as primers for polymerase chain reaction (PCR) or for probes for the presence and level of transcription of a glycosyltransferase gene.

15 In specific embodiments, exemplified herein, the nucleic acid encodes a glycosyltransferase having an amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:8.

The invention further relates to an expression vector comprising the nucleic acid encoding a glycosyltransferase of the invention operatively associated with an 20 expression control sequence. Accordingly, the invention extends to recombinant host cell transformed with such an expression vector.

In another aspect, the invention is directed to a method for producing a glycosyltransferase comprising culturing the recombinant host cell under conditions that allow expression of the glycosyltransferase; and recovering the expressed 25 glycosyltransferase.

In a primary aspect, the invention is directed to glycosyltransferase having an amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:8, a functionally active fragment thereof. The invention further contemplates a composition comprising a glycosyltransferase conjugated to

5 a solid phase support, wherein the glycosyltransferase is selected from the group consisting of a glycosyltransferase having an amino acid sequence of SEQ ID NO:3, or a functionally active fragment thereof; a glycosyltransferase having an amino acid sequence of SEQ ID NO:8, or a functionally active fragment thereof; a glycosyltransferase having an amino acid sequence of SEQ ID NO:4, or a

10 functionally active fragment thereof; and a glycosyltransferase having an amino acid sequence of SEQ ID NO:5, or a functionally active fragment thereof; and a glycosyltransferase having an amino acid sequence of SEQ ID NO:6, or a functionally active fragment thereof.

Having provided novel glycosyltransferases, and genes encoding the same, the

15 invention accordingly further provides methods for preparing oligosaccharides, e.g., two or more saccharides. In specific embodiments, the invention relates to a method for adding GalNAc or GlcNAc $\beta 1 \rightarrow 3$ to Gal, comprising contacting a reaction mixture comprising an activated GalNAc or GlcNAc to an acceptor moiety comprising a Gal residue in the presence of the glycosyltransferase having

20 an amino acid sequence of SEQ ID NO:3; a method for adding Gal $\alpha 1 \rightarrow 4$ to GlcNAc or Glc, comprising contacting a reaction mixture comprising an activated Gal to an acceptor moiety comprising a GlcNAc or Glc residue in the presence of the glycosyltransferase having an amino acid sequence of SEQ ID NO:8; a method for adding Gal $\alpha 1 \rightarrow 4$ to Gal, comprising contacting a reaction mixture comprising

25 an activated Gal to an acceptor moiety comprising a Gal residue in the presence of the glycosyltransferase having an amino acid sequence of SEQ ID NO:4; a method for adding GalNAc or GlcNAc $\beta 1 \rightarrow 3$ to Gal, comprising contacting a reaction mixture comprising an activated GalNAc or GlcNAc to an acceptor moiety comprising a Gal residue in the presence of the glycosyltransferase having an

30 amino acid sequence of SEQ ID NO:5; and a method for adding Gal $\beta 1 \rightarrow 4$ to

GlcNAc or Glc, comprising contacting a reaction mixture comprising an activated Gal to an acceptor moiety comprising a GlcNAc or Glc residue in the presence of the glycosyltransferase having an amino acid sequence of SEQ ID NO:6.

In a preferred embodiment, the oligosaccharides are prepared on a carrier that is

5 non-toxic to a mammal, in particular a human, such as a lipid isoprenoid or polyisoprenoid alcohol. A specific example of such a carrier is dolichol phosphate. In a specific embodiment, the oligosaccharide is attached to the carrier via a labile bond, thus allowing for chemically removing the oligosaccharide from the lipid carrier. Alternatively, an oligosaccharide transferase can be used, e.g.,

10 to transfer the oligosaccharide from a lipid carrier to a protein. In yet another embodiment, the glycosyltransferases can be expressed in a eukaryotic expression system, to provide for glycosylation of a protein expressed in such a system.

An important advantage of the present invention is that it provides for the synthesis of oligosaccharide antigens of *Neisseria* independently of lipid A, which

15 is highly toxic. Use of the natural LOS from *Neisseria*, while theoretically desirable for vaccine preparation, fails. The lipid A portion of LOS is a potent endotoxin, and highly toxic. Chemical treatment of the LOS, e.g., by hydrolysis, destroys the antigenicity of the oligosaccharide, leaving a useless product. Thus,

20 it is highly desirable to have a source of *Neisseria* oligosaccharides attached to non-toxic lipids for vaccine preparation.

Thus, the invention provides glycosyltransferases and strategies for preparing a number of oligosaccharides, such as but not limited to, $\text{Gal}\alpha 1\rightarrow 4\text{Gal}\beta 1\rightarrow 4\text{Glc}$, $\text{Gal}\beta 1\rightarrow 4\text{GlcNAc}\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 4\text{Glc}$, and $\text{GalNAc}\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 4\text{GlcNAc}\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 4\text{Glc}$.

25 Accordingly, it is a primary object of the invention to provide glycosyltransferases useful for the synthesis of oligosaccharides.

10

It is a further object of the invention to provide for the synthesis of oligosaccharides characteristic of *Neisseria meningitidis* and *N. gonorrhoeae*.

It is a further object of the invention to provide for the synthesis of oligosaccharides characteristic of mammalian oligosaccharides, including blood

5 group core oligosaccharides.

It is still a further object of the invention to provide for vaccines having the oligosaccharide unit of LOS, but lacking lipid A.

Still a further object of the invention is to provide for synthesis of therapeutically useful oligosaccharides.

10 These and other objects of the present will be made clear by reference to the following Drawings and Detailed Description.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Alternative structures found in gonococcal LOS. R1 refers to the inner core region of LOS consisting of two keto-deoxy-octulosonic acid (KDO) residues.

15 These in turn are attached to a lipid A structure. R2 in gonococci is typically GlcNAc β 1 \rightarrow 2Hep α 1 \rightarrow 3. The structure in the top panel contains a tetrasaccharide identical to lacto-N-neotetraose found in paragloboside glycolipids. In many strains this tetrasaccharide bears a terminal GalNAc β 1 \rightarrow 3. The lower panel shows an alternative trisaccharide structure with the terminal Gal α 1 \rightarrow 4 linked. This
20 trisaccharide is seen in meningococci of the L1 serotype and in some gonococcal strains. The portions of the two structures recognized by the monoclonal antibodies used in this study are indicated (4C4) (Dudas and Apicella, 1988, Infect. Immun. 56:499) 3F11 (Mandrell et al., 1988, J. Exp. Med. 168:107; Yamasaki et al., 1991, Mol. Immunol. 28:1233) 1-1-M (Yamasaki et al., 1991, Mol. Immunol. 28:1233), 2-1-L8 (Kerwood et al., 1992, Biochemistry 31:12760;

Schneider et al., 1991, J. Exp. Med. 174:1601; Schneider et al., 1985, Infect. Immun. 50:672) 9-2-L378 and 17-1-L1.

Figure 2: (A) Genetic map of the LOS locus based on the DNA sequence. Sequence information bp 1-2725 was obtained from plasmid pPstCla, bp 2725-5 5859 from plasmid p3400 (see materials and methods). IS refers to an area of the sequence that has homology to a previously reported neisserial insertion sequence IS1106 (Knight et al., 1992, Molec. Microbiol. 6:1565). The positions of the reading frames of *lgtA-E* are indicated. Three tracts of poly-G were found in *lgtA* (17 bp), *lgtC* (10 bp) and *lgtD* (11 bp) and are indicated by vertical black bars.

10 Amino acid sequences of (B) LgtA (SEQ ID NO:3), (C) LgtB (SEQ ID NO:8), (D) LgtC (SEQ ID NO:4), (E) LgtD (SEQ ID NO:5), and (F) LgtE (SEQ ID NO:6), and (G-M) the nucleotide sequence of the lgt locus (SEQ ID NO:1).

Figure 3(A,B): Homology of the protein products of *lgtA* and *lgtD*. The primary structure of two proteins is very similar, particularly in the first half of the sequences. The glycine residues starting at position 86 reflect the coding of the poly-G regions in the respective genes. The Bestfit program of the GCG package was used and the symbols |, :, . represent degrees of similarity based on the Dayhoff PAM-250 matrix.

Figure 4(A,B): Homology of the protein products of *lgtB* and *lgtE*. The primary structure of two proteins is very similar, particularly in the first half of the sequences. These sequences also have significant homology to *lex-1* (Cope et al., 1991, Molec. Microbiol. 5:1113) or *lic2A* (High et al., 1993, Molec. Microbiol. 9:1275) genes of *Haemophilus influenzae*. For meaning of symbols see Figure 3.

Figure 5(A,B): Homology of the protein products of *rfaI* and *lgtC*. The *E. coli* 25 *rfaI* and *rfaJ* genes are very closely related. They serve as glucosyl transferases of two glucose residues in the LPS core region (Pradel et al., 1992, J. Bacteriol.

174:4736). The glycines at position 54-56 in *IgtC* are encoded by the poly-G tract. For meaning of symbols see Figure 3.

Figure 6: Deletions in the LOS locus. Three insertion and five deletions of the LOS locus were constructed as detailed in the methods section. The restriction sites that were used are indicated. The insertions are marked by triangles and the extent of the deletions by stippled boxes. The open arrows indicate the open reading frames disrupted by the construction. In each of the constructs the erythromycin marker *ermC'* was inserted at the site of the insertion or the deletion.

Figure 7: Silver-stained SDS-PAGE of LOS preparations. Gel electrophoresis of purified LOS samples of 375 ng was performed and stained as described in materials and methods. Above the gel are indicated the structure of the LOS of the major bands inferred to be present in each of the preparations. These structures are based on the reactivity with monoclonal antibodies shown in Figure 8, but are presented in this Figure to facilitate interpretation of the patterns observed. R stands for the inner core region and lipid A. 1291e is a pyocin resistant mutant (Dudas and Apicella, 1988, Infect. Immun. 56:499)

Figure 8: Reactivity of LOS from strain F62 wt and mutants with monoclonal antibodies. The names of the following monoclonal antibodies were abbreviated: 17-1-L1 (L1), 9-2-L378 (L3), 2-1-L8 (L8). Purified LOS was applied to Immobilon-P membranes, allowed to react with the antibodies and developed as described in materials and methods. The specificity of the monoclonal antibodies is summarized in Figure 1.

DETAILED DESCRIPTION OF THE INVENTION

As disclosed above, the present invention provides five novel glycosyltransferases, genes encoding the glycosyltransferases, and methods for biosynthesis of

oligosaccharides using such glycosyltransferases. The glycosyl transferases of the invention can be used for *in vitro* biosynthesis of various oligosaccharides, such as the core oligosaccharide of the human blood group antigens, *i.e.*, lacto-N-neotetraose.

- 5 Cloning and expression of glycosyltransferases of the invention can be accomplished using standard techniques, as disclosed herein. Such glycosyl transferases are useful for biosynthesis of oligosaccharides *in vitro*, or alternatively genes encoding such glycosyltransferases can be transfected into cells, *e.g.*, yeast cells or eukaryotic cells, to provide for alternative glycosylation of proteins and
- 10 lipids.

The instant invention is based, in part, on the discovery and cloning of a locus involved in the biosynthesis of gonococcal LOS has from gonococcal strain F62. The locus contains five open reading frames. The first and the second reading frames are homologous, but not identical to the fourth and the fifth reading frames 15 respectively. Interposed is an additional reading frame which has distant homology to the *E. coli rfaI* and *rfaJ* genes, both glucosyl transferases involved in LPS core biosynthesis. The second and the fifth reading frames show strong homology to the *lex-1* or *lic2A* gene of *Haemophilus influenzae*, but do not contain the CAAT repeats found in this gene. Deletions of each of these five 20 genes, of combinations of genes, and of the entire locus were constructed and introduced into parental gonococcal strain F62 by transformation. The LOS phenotypes were then analyzed by SDS-PAGE and reactivity with monoclonal antibodies. Analysis of the gonococcal mutants indicates that four of these genes are the glycosyl transferases that add GalNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4 25 to the substrate Glc β 1 \rightarrow 4Hep \rightarrow R of the inner core region. The gene with homology to *E. coli rfaI/rfaJ* is involved with the addition of the α -linked galactose residue in the biosynthesis of the alternative LOS structure Gal α 1 \rightarrow 4Gal β 1 \rightarrow 4Glc β 1 \rightarrow 4Hep \rightarrow R.

Since these genes encode LOS glycosyl transferases they have been named *lgtA*, *lgtB*, *lgtC*, *lgtD* and *lgtE*. The DNA sequence analysis revealed that *lgtA*, *lgtC* and *lgtD* contain poly-G tracts, which in strain F62 were respectively 17, 10 and 11 bp. Thus, three of the LOS biosynthetic enzymes are potentially susceptible to 5 premature termination by reading-frame changes. It is likely that these structural features are responsible for the high frequency genetic variation of gonococcal LOS.

Abbreviations used throughout this specification include: Lipopolysaccharide, LPS; Lipooligosaccharide, LOS; N-Acetyl-neuraminic acid cytidine mono phosphate, 10 CMP-NANA; wild type, wt; Gal, galactose; Glc, glucose; NAc, N-acetyl (e.g., GalNAc or GlcNAc).

In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., 15 Sambrook, Fritsch & Maniatis, "Molecular Cloning: A Laboratory Manual," Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (herein "Sambrook et al., 1989"); "DNA Cloning: A Practical Approach," Volumes I and II (D.N. Glover ed. 1985); "Oligonucleotide Synthesis" (M.J. Gait ed. 1984); "Nucleic Acid Hybridization" [B.D. Hames & 20 S.J. Higgins eds. (1985)]; "Transcription And Translation" [B.D. Hames & S.J. Higgins, eds. (1984)]; "Animal Cell Culture" [R.I. Freshney, ed. (1986)]; "Immobilized Cells And Enzymes" [IRL Press, (1986)]; B. Perbal, "A Practical Guide To Molecular Cloning" (1984).

Therefore, if appearing herein, the following terms shall have the definitions set 25 out below.

A cell has been "transformed" by exogenous or heterologous DNA when such DNA has been introduced inside the cell; the cell may express a gene or genes

encoded by such DNA. The transforming DNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell, or may be contained on an autonomous replicon. In prokaryotes, yeast, and mammalian cells for example, the transforming DNA may be maintained on an 5 episomal element such as a plasmid. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis.

A "nucleic acid molecule" refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, uridine or cytidine; "RNA molecules") or deoxyribonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or 10 deoxycytidine; "DNA molecules") in either single stranded form, or a double-stranded helix. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible. The term nucleic acid molecule, and in particular DNA or RNA molecule, refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double- 15 stranded DNA found, *inter alia*, in linear or circular DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e., the strand 20 having a sequence homologous to the mRNA). A "recombinant DNA molecule" is a DNA molecule that has undergone a molecular biological manipulation.

A nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate 25 conditions of temperature and solution ionic strength (see Sambrook et al., 1989, *supra*). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate

16

stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T_m for hybrids of nucleic acids having those sequences. The 5 relative stability (corresponding to higher T_m) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating T_m have been derived (see Sambrook et al., *supra*, 9.50-9.51). For hybridization with shorter nucleic acids, *i.e.*, oligonucleotides, the position of mismatches becomes 10 more important, and the length of the oligonucleotide determines its specificity (see Sambrook et al., *supra*, 11.7-11.8). Preferably a minimum length for a hybridizable nucleic acid is at least about 10 nucleotides; more preferably at least about 15 nucleotides; most preferably the length is at least about 20 nucleotides.

A DNA "coding sequence" is a double-stranded DNA sequence which is 15 transcribed and translated into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA 20 sequences from eukaryotic (e.g., mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.

Transcriptional and translational control sequences are DNA regulatory sequences, 25 such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell. Although the individual genes encoding glycosyltransferases of the invention are found in a single locus with very short non-coding sequences between them, phase variation resulting in deletion of any of *lgtA*, *lgtB*, or *lgtC* does not preclude reinitiation of transcription

at the downstream genes. Thus, the locus provided herein includes transcription initiation sequences for transcription in *Neisseria*. Alternatively, the coding sequences of the invention can be engineered for expression under control of heterologous control sequences.

- 5 A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or
- 10 elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site (conveniently defined for example, by mapping with nuclease S1), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes.
- 15

A coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA, which is then translated into the protein encoded by the coding sequence.

- 20 A "signal sequence" can be included before the coding sequence. This sequence encodes a signal peptide, N-terminal to the polypeptide, that directs the host cell to translocate the polypeptide to the cell surface or to organelles within the cell, or secrete the polypeptide into the media, and this signal peptide is usually selectively cleaved by the protein transport machinery. Signal sequences can be found
- 25 associated with a variety of proteins native to prokaryotes and eukaryotes. Incorporation of a signal sequence may be desirable for high level expression of a glycosyltransferase of the invention by bacteria, yeast, insect cells (baculovirus), or eukaryotic cells, to avoid affecting endogenous glycosylation in the host cell.

A molecule is "antigenic" when it is capable of specifically interacting with an antigen recognition molecule of the immune system, such as an immunoglobulin (antibody) or T cell antigen receptor. As mentioned above, the carbohydrate (oligosaccharide) moiety of the LOS of *Neisseria* is an important antigenic determinant, which determines serotype of meningococcus (Zollinger and Mandrell, 1977, Infect. Immun. 18:424; Zollinger and Mandrell, 1980, Infect. Immun. 28:451). An antigenic portion of a molecule can be that portion that is immunodominant for antibody, or it can be a portion used to generate an antibody to the molecule by conjugating the antigenic portion to a carrier molecule for immunization. A molecule that is antigenic need not be itself immunogenic, i.e., capable of eliciting an immune response without a carrier.

A composition comprising "A" (where "A" is a single protein, DNA molecule, vector, etc.) is substantially free of "B" (where "B" comprises one or more contaminating proteins, DNA molecules, vectors, etc.) when at least about 75% by weight of the proteins, DNA, vectors (depending on the category of species to which A and B belong) in the composition is "A". Preferably, "A" comprises at least about 90% by weight of the A+B species in the composition, most preferably at least about 99% by weight. It is also preferred that a composition, which is substantially free of contamination, contain only a single molecular weight species having the activity or characteristic of the species of interest.

The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered. Such pharmaceutical carriers can be

sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for
5 injectable solutions. Pharmaceutically acceptable compositions of the invention are free of amounts of lipid A effective to cause a response in a mammalian subject, in particular a human subject.

The term "adjuvant" refers to a compound or mixture that enhances the immune response to an antigen. An adjuvant can serve as a tissue depot that slowly
10 releases the antigen and also as a lymphoid system activator that non-specifically enhances the immune response (Hood et al., *Immunology, Second Ed.*, 1984, Benjamin/Cummings: Menlo Park, California, p. 384). Often, a primary challenge with an antigen alone, in the absence of an adjuvant, will fail to elicit a humoral or cellular immune response. Adjuvants include, but are not limited to,
15 complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*. Preferably, the
20 adjuvant is pharmaceutically acceptable.

Isolation of Genes for Glycosyltransferases

The present invention provides the full length coding sequence of the LOS locus of *Neisseria*, and thus, allows for obtaining any one or all five genes, termed herein *lgt* genes, encoding glycosyltransferases characteristic of that locus. Any *Neisseria*
25 bacterial cell can potentially serve as the nucleic acid source for the molecular cloning of an *lgt* gene. In a specific embodiment, *infra*, the genes are isolated from *Neisseria gonorrhoeae*. The DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a DNA "library"), by chemical

synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (See, for example, Sambrook et al., 1989, *supra*; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II). For example, a *N. gonorrhoeae* genomic

5 DNA can be digested with a restriction endonuclease or endonucleases, e.g., *Sau3A*, into a phage vector digested with a restriction endonuclease or endonucleases, e.g., *BamHI/EcoRI*, for creation of a phage genomic library. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

10 In the molecular cloning of the gene from genomic DNA, DNA fragments are generated, some of which will encode the desired gene. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNase in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments

15 can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired *lgt* gene may be accomplished in a number of ways. For example, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe synthesized with a sequence as disclosed herein (Benton and Davis, 1977, Science 196:180; Grunstein and Hogness, 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961). Those DNA fragments with substantial homology to the probe will hybridize. The present invention provides specific examples of DNA fragments that can be used as hybridization probes for glycosyltransferases, e.g., SEQ ID NO:1.

As described above, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For

example DNA clones that produce a protein that, e.g., has similar or identical electrophoretic migration, isoelectric focusing behavior, proteolytic digestion maps, proteolytic activity, or functional properties, in particular glycosyltransferase activity the ability of a Lgt protein to mediate transfer of a sugar to an acceptor molecule. Alternatively, the putative *lgt* gene can be mutated, and its role as a glycosyltransferase established by detecting a variation in the structure of the oligosaccharide of LOS.

Alternatives to isolating the *lgt* genomic DNA include, but are not limited to, chemically synthesizing the gene sequence itself from a known sequence that encodes an Lgt, e.g., as shown in SEQ ID NO:1. In another embodiment, DNA for an *lgt* gene can be isolated PCR using oligonucleotide primers designed from the nucleotide sequences disclosed herein. Other methods are possible and within the scope of the invention.

The identified and isolated gene can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. In a specific aspect of the invention, the *lgt* coding sequence is inserted in an *E. coli* cloning vector. Other examples of vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 derivatives or pUC plasmid derivatives, e.g., pGEX vectors, pmal-c, pFLAG, etc. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In specific embodiment, PCR primers containing such

linker sites can be used to amplify the DNA for cloning. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

Transformation of host cells with recombinant DNA molecules that incorporate the

5 isolated *lgt* gene or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

10 The present invention also relates to vectors containing genes encoding truncated forms of the enzyme (fragments) and derivatives of Lgt's that have the same functional activity as an Lgt. The production and use of fragments and derivatives related to an Lgt are within the scope of the present invention. In a specific embodiment, the fragment or derivative is functionally active, *i.e.*, capable of

15 mediating transfer of a sugar to an acceptor molecule.

Truncated fragments of the glycosyltransferases can be prepared by eliminating N-terminal, C-terminal, or internal regions of the protein that are not required for functional activity. Usually, such portions that are eliminated will include only a few, *e.g.*, between 1 and 5, amino acid residues, but larger segments may be

20 removed.

Chimeric molecules, *e.g.*, fusion proteins, containing all or a functionally active portion of a glycosyltransferase of the invention joined to another protein are also envisioned. A glycosyltransferase fusion protein comprises at least a functionally active portion of a non-glycosyltransferase protein joined via a peptide bond to at

25 least a functionally active portion of a glycosyltransferase polypeptide. The non-glycosyltransferase sequences can be amino- or carboxy-terminal to the glycosyltransferase sequences. Expression of a fusion protein can result in an

enzymatically inactive glycosyltransferase fusion protein. A recombinant DNA molecule encoding such a fusion protein comprises a sequence encoding at least a functionally active portion of a non-glycosyltransferase protein joined in-frame to the glycosyltransferase coding sequence, and preferably encodes a cleavage site for 5 a specific protease, e.g., thrombin or Factor Xa, preferably at the glycosyltransferase-non-glycosyltransferase juncture. In a specific embodiment, the fusion protein may be expressed in *Escherichia coli*.

In particular, Lgt derivatives can be made by altering encoding nucleic acid sequences by substitutions, additions or deletions that provide for functionally 10 equivalent molecules. Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as an *lgt* gene may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of *lgt* genes that are altered by the substitution of different codons that encode the same amino 15 acid residue within the sequence, thus producing a silent change. Likewise, the Lgt derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of an Lgt including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a conservative 20 amino acid substitution. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity, which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, 25 tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

The genes encoding Lgt derivatives and analogs of the invention can be produced by various methods known in the art (*e.g.*, Sambrook et al., 1989, *supra*). The sequence can be cleaved at appropriate sites with restriction endonuclease(s), followed by further enzymatic modification if desired, isolated, and ligated *in vitro*. In the production of the gene encoding a derivative or analog of Lgt, care should be taken to ensure that the modified gene remains within the same translational reading frame as the *lgt* gene, uninterrupted by translational stop signals, in the gene region where the desired activity is encoded.

Additionally, the *lgt* nucleic acid sequence can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. Any technique for mutagenesis known in the art can be used, including but not limited to, *in vitro* site-directed mutagenesis (Hutchinson, C., et al., 1978, *J. Biol. Chem.* 253:6551; Zoller and Smith, 1984, *DNA* 3:479-488; Oliphant et al., 1986, *Gene* 44:177; Hutchinson et al., 1986, *Proc. Natl. Acad. Sci. U.S.A.* 83:710), use of TAB® linkers (Pharmacia), etc. PCR techniques are preferred for site directed mutagenesis (see Higuchi, 1989, "Using PCR to Engineer DNA", in *PCR Technology: Principles and Applications for DNA Amplification*, H. Erlich, ed., Stockton Press, Chapter 6, pp. 61-70). It is notable in this regard that the *lgtA*, *lgtB*, and *lgtC* genes contain long poly-G stretches that are particularly susceptible to phase variation mutation.

Expression of a Glycosyltransferase

The gene coding for an Lgt, or a functionally active fragment or other derivative thereof, can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. An expression vector also preferably includes a replication origin. The necessary transcriptional and translational signals can also

be supplied by the native *lgt* gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence.

Preferably, however, a bacterial expression system is used to provide for high level expression of the protein with a higher probability of the native

- 5 conformation. Potential host-vector systems include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary
- 10 in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

Preferably, the periplasmic form of the Lgt (containing a signal sequence) is produced for export of the protein to the *Escherichia coli* periplasm or in an

- 15 expression system based on *Bacillus subtilis*.

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the

- 20 protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination).

Expression of nucleic acid sequence encoding an glycosyltransferase or peptide fragment may be regulated by a second nucleic acid sequence so that the glycosyltransferase or peptide is expressed in a host transformed with the

- 25 recombinant DNA molecule. For example, expression of an glycosyltransferase may be controlled by any promoter/enhancer element known in the art, but these regulatory elements must be functional in the host selected for expression. For expression in bacteria, bacterial promoters are required. Eukaryotic viral or eukaryotic promoters, including tissue specific promoters, are preferred when a

vector containing an *lgt* gene is injected directly into a subject for transient expression, resulting in heterologous protection against bacterial infection, as described in detail below. Promoters which may be used to control *lgt* gene expression include, but are not limited to, the SV40 early promoter region
5 (Benoist and Chambon, 1981, *Nature* 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, *Cell* 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, *Proc. Natl. Acad. Sci. U.S.A.* 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, *Nature* 296:39-42); prokaryotic
10 expression vectors such as the β -lactamase promoter (Villa-Kamaroff, et al., 1978, *Proc. Natl. Acad. Sci. U.S.A.* 75:3727-3731), or the *tac* promoter (DeBoer, et al., 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:21-25); see also "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242:74-94; and the like

Expression vectors containing *lgt* gene inserts can be identified by four general
15 approaches: (a) PCR amplification of the desired plasmid DNA or specific mRNA, (b) nucleic acid hybridization, (c) presence or absence of "marker" gene functions, and (d) expression of inserted sequences. In the first approach, the nucleic acids can be amplified by PCR with incorporation of radionucleotides or stained with ethidium bromide to provide for detection of the amplified product. In the second
20 approach, the presence of a foreign gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted *lgt* gene. In the third approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., β -galactosidase activity, PhoA
25 activity, thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. If the *lgt* gene is inserted within the marker gene sequence of the vector, recombinants containing the *lgt* insert can be identified by the absence of the marker gene function. In the fourth approach, recombinant
30 expression vectors can be identified by assaying for the activity of the *lgt* gene

product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the *lgt* gene product in *in vitro* assay systems, *e.g.*, glycosyltransferase activity. Once a suitable host system and growth conditions are established, recombinant expression vectors can be
5 propagated and prepared in quantity.

Biosynthesis of Oligosaccharides

The glycosyltransferases of the present invention can be used in the biosynthesis of oligosaccharides. The glycosyltransferases of the invention are capable of stereospecific conjugation of a specific activated saccharide unit to a specific
10 acceptor molecule. Such activated saccharides generally consist of uridine, guanosine, and cytidine diphosphate derivatives of the saccharides, in which the nucleoside diphosphate serves as a leaving group. Thus, the activated saccharide may be a saccharide-UDP, a saccharide-GDP, or a saccharide-CDP. In specific
15 embodiments, the activated saccharide is UDP-GlcNAc, UDP-GalNAc, or UDP-Gal.

The term "acceptor molecule" as used herein refers to the molecule to which the glycosyltransferase transfers an activated sugar. As is well known in the art, synthesis of carbohydrates proceeds by sequential coupling of sugar residues to a lipid, *e.g.*, dolichol phosphate. In eukaryotic cells, which glycosylate proteins, the
20 oligosaccharide or polysaccharide is transferred from the activated lipid carrier to the polypeptide on the luminal side of the endoplasmic reticulum. In prokaryotes, the carbohydrate can be synthesized directly on a lipid A molecule. It is likely that the glycosyltransferases of the invention may be sensitive to the core portion of the growing carbohydrate and the lipid molecule. Thus, in a preferred aspect,
25 the acceptor molecule, or carrier, contains a lipid, preferably a polyisoprenoid alcohol lipid such as dolichol phosphate. Maximum synthetic efficiency may ensue from use of lipid A as the carrier. While the lipid A is not useful as a carrier for direct administration of the resulting oligosaccharide to a subject, *e.g.*,

as a vaccine preparation, it may be appropriate for use with a labile linkage for subsequent cleavage (under mild conditions) and separation of the oligosaccharide from the lipid carrier. It should further be noted that the glycosyltransferases will only work efficiently to add a specific activated saccharide to a saccharide residue
5 on the acceptor molecule that corresponds to the natural acceptor molecule. For example, LgtE catalyzes transfer of Gal to Glc β 1-4Hep. Thus, where a glycosyltransferase mediates attachment of GalNAc to Glc, the nature of the Glc residue (whether it is attached directly or indirectly to the carrier, for example) will affect the reaction efficiency. It is unlikely that efficient synthesis can occur
10 in the absence of a carrier, or using other than a lipid carrier. However, even inefficient synthesis may be desirable, and practice of the present invention is not limited to use of acceptor molecules containing lipids, but extends to saccharides, polysaccharides, polypeptides, glycoproteins, and the like.

For the synthesis of an oligosaccharide, a glycosyltransferase is contacted with an
15 appropriate activated saccharide and an appropriate acceptor molecule under conditions effective to transfer and covalently bond the saccharide to the acceptor molecule. Conditions of time, temperature, and pH appropriate and optimal for a particular saccharide unit transfer can be determined through routine testing; generally, physiological conditions will be acceptable. Certain co-reagents may
20 also be desirable; for example, it may be more effective to contact the glycosyltransferase with the activated saccharide and the acceptor molecule in the presence of a divalent cation.

According to the invention, the glycosyltransferase enzymes can be covalently or non-covalently immobilized on a solid phase support such as SEPHADEX,
25 SEPHAROSE, or poly(acrylamide-co-N-acryloxysuccinimide) (PAN) resin. A specific reaction can be performed in an isolated reaction solution, with facile separation of the solid phase enzyme from the reaction products. Immobilization of the enzyme also allows for a continuous biosynthetic stream, with the specific glycosyltransferases attached to a solid support, with the supports arranged

randomly or in distinct zones in the specified order in a column, with passage of the reaction solution through the column and elution of the desired oligosaccharide at the end. An efficient method for attaching the glycosyltransferase to a solid support and using such immobilized glycosyltransferases is described in U.S.

5 Patent No. 5,180,674, issued January 19, 1993 to Roth, which is specifically incorporated herein by reference in its entirety.

An oligosaccharide, *e.g.*, a disaccharide, prepared using a glycosyltransferase of the present invention can serve as an acceptor molecule for further synthesis, either using other glycosyltransferases of the invention, or glycosyltransferases

10 known in the art (*see, e.g.*, Roth, U.S. Patent No. 5,180,674, and Roth, International Patent Publication No. WO 93/13198, published 8 July 1993, each of which is incorporated herein by reference in its entirety). The oligosaccharide compositions of the invention are useful in a wide variety of therapeutic and diagnostic applications. For example, the saccharide compositions can be used as
15 blocking agents for cell surface receptors in the treatment of numerous diseases involving cellular adhesion. Alternatively, saccharide compositions useful as nutritional supplements, antibacterials, anti-metastases agents, anti-inflammatory agents (*e.g.*, for binding to inflammatory-associated lectins or cell surface receptors), to mention but a few, are contemplated by the instant invention. As
20 noted above, the glycosyltransferases of the invention can be used in conjunction with other glycosyltransferases known in the art or to be discovered to synthesize complex oligosaccharides or polysaccharides.

Alternatively, the glycosyltransferases of the invention can be used to synthesize oligosaccharides representative of the oligosaccharides found on various strains of
25 *Neisseria*. For example, by deleting open reading frames from the locus, or by selecting only a few of the glycosyltransferases of the invention for synthesis, alternative oligosaccharide structures can be prepared. These can be used in vaccine preparations effective against *Neisseria* variants, in particular, subunit vaccines against gonococcus and meningococcus.

Alternatively, the glycosyltransferases of the present invention can be used to prepare oligosaccharides corresponding to oligosaccharides associated with human glycolipids. Thus, in specific embodiments, the present invention provides for synthesis of an oligosaccharide corresponding to lacto-N-neotetraose of the 5 sphingolipid paragloboside; an oligosaccharide that mimics gangliosides; and a mimic of the saccharide portion of globoglycolipids, which is the structure characteristically found in *Neisseria meningitidis* immunotype L1. The oligosaccharides of the present invention correspond to the core oligosaccharides of the blood group antigens, and therefore have great utility in the preparation of 10 such blood group antigens for diagnostic or therapeutic purposes.

Accordingly, a method for preparing an oligosaccharide having the structure GalNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc (*i.e.*, ganglioside) comprises sequentially performing the steps of:

- a. contacting a reaction mixture comprising an activated Gal to an 15 acceptor moiety comprising a Glc residue in the presence of a glycosyltransferase having an amino acid sequence of SEQ ID NO: 6, or a functionally active fragment thereof;
- b. contacting a reaction mixture comprising an activated GlcNAc to the acceptor moiety comprising a Gal β 1 \rightarrow 4Glc residue in the presence of a 20 glycosyltransferase having an amino acid sequence of SEQ ID NO:3, or a functionally active fragment thereof;
- c. contacting a reaction mixture comprising an activated Gal to the acceptor moiety comprising a GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc residue in the presence of a glycosyltransferase having an amino acid of SEQ ID NO:8; 25 and
- d. contacting a reaction mixture comprising an activated GalNAc to the acceptor moiety comprising a Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc residue in the presence of a glycosyltransferase having an amino acid sequence of SEQ ID NO:5, or a functionally active fragment thereof.

Similarly, a method for preparing an oligosaccharide having the structure $\text{Gal}\beta 1\rightarrow 4\text{GlcNAc}\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 4\text{Glc}$ (*i.e.*, lacto-N-neotetraose) comprises sequentially performing the steps of:

- a. contacting a reaction mixture comprising an activated Gal to an acceptor moiety comprising a Glc residue in the presence of a glycosyltransferase having an amino acid sequence of SEQ ID NO: 6, or a functionally active fragment thereof;
- b. contacting a reaction mixture comprising an activated GlcNAc to the acceptor moiety comprising a $\text{Gal}\beta 1\rightarrow 4\text{Glc}$ residue in the presence of a glycosyltransferase having an amino acid sequence of SEQ ID NO:3, or a functionally active fragment thereof; and
- c. contacting a reaction mixture comprising an activated Gal to the acceptor moiety comprising a $\text{GlcNAc}\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 4\text{Glc}$ residue in the presence of a glycosyltransferase having an amino acid of SEQ ID NO:8.

In another embodiment, a method for preparing an oligosaccharide having the structure $\text{Gal}\alpha 1\rightarrow 4\text{Gal}\beta 1\rightarrow 4\text{Glc}$ (*i.e.*, globoglycolipids) comprises sequentially performing the steps of:

- a. contacting a reaction mixture comprising an activated Gal to an acceptor moiety comprising a Glc residue in the presence of a glycosyltransferase having an amino acid sequence of SEQ ID NO:6, or a functionally active fragment thereof; and
- b. contacting a reaction mixture comprising an activated Gal to the acceptor moiety comprising $\text{Gal}\beta 1\rightarrow 4\text{Glc}$ in the presence of a glycosyltransferase having an amino acid sequence of SEQ ID NO:4, or a functionally active fragment thereof.

Such oligosaccharides can be prepared using lipid A as a carrier. Preferably, if the resulting glycolipid is to be used in a vaccine, a non-toxic lipid, such as dolichol phosphate, is used as the carrier.

Vaccination

Active immunity against *Neisseria* strains can be induced by immunization (vaccination) with an immunogenic amount of an oligosaccharide prepared according to the present invention in admixture with an adjuvant, wherein the 5 oligosaccharide is the antigenic component of the vaccine. Preferably, the oligosaccharide is conjugated to a carrier protein. Alternatively, where the antigen is a glycolipid, it can be incorporated in a liposome.

The oligosaccharide alone cannot cause bacterial infection, although the 10 oligosaccharide on lipid A is toxic, and the active immunity elicited by vaccination according to the present invention can result in immediate immune response.

Selection of an adjuvant depends on the subject to be vaccinated. Preferably, a pharmaceutically acceptable adjuvant is used. For example, a vaccine for a human should avoid oil or hydrocarbon emulsion adjuvants, including complete and incomplete Freund's adjuvant. One example of an adjuvant suitable for use with 15 humans is alum (alumina gel). A vaccine for an animal, however, may contain adjuvants not appropriate for use with humans.

A vaccine of the invention, i.e., a vaccine comprising an oligosaccharide corresponding to an antigenic determinant on a strain of *Neisseria*, can be administered via any parenteral route, including but not limited to intramuscular, 20 intraperitoneal, intravenous, and the like.

Administration of an amount of a *Neisseria* oligosaccharide sufficient to inhibit adhesion of the bacterium to its target cell may also be effective for treating meningococcal or gonococcal infection. The required amount can be determined by one of ordinary skill using standard techniques.

Expression of Glycosyltransferases in for Intracellular Glycosylation

The present invention further contemplates transforming a host cell with a glycosyltransferase or glycosyltransferases of the invention. It is expected that expression of the glycosyltransferase, possibly in a cell lacking one or more

5 endogenous glycosyltransferases, may result in novel glycosylation of lipids and proteins in such eukaryotic cells, and novel glycosylation of lipids in prokaryotic cells.

For example, transformation of a bacterium with non-toxic lipid molecules may provide for expression of *Neisseria* oligosaccharides on such a bacterium, which

10 can then be used directly in a whole cell vaccine.

Alternatively, expression of such a glycosyl transferase in yeast, insect, or mammalian cell lines may result in novel glycosylation of lipids and proteins expressed by these cells.

Antibodies to *Neisseria* Oligosaccharides, and Diagnosis and Therapy Therewith

15 Just as the oligosaccharides can be used in vaccines, so to they can be used to generate antibodies to themselves, which antibodies, in turn, can be used to detect that particular strain of bacteria or for passive immunity. Antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. Various procedures known in the art may be used

20 for the production of polyclonal antibodies to oligosaccharide. For the production of antibody, various host animals can be immunized by injection with the oligosaccharide, including but not limited to rabbits, mice, rats, sheep, goats, etc. In one embodiment, the oligosaccharide can be conjugated to an immunogenic carrier, e.g., bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH).

25 Various adjuvants may be used to increase the immunological response, depending on the host species. For preparation of monoclonal antibodies directed toward the

oligosaccharide, or fragment, analog, or derivative thereof, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique originally developed by Kohler and Milstein (1975, *Nature* 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545). According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote et al., 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:2026-2030) or by transforming human B cells with EBV virus *in vitro* (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, pp. 77-96). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, *J. Bacteriol.* 159:870; Neuberger et al., 1984, *Nature* 312:604-608; Takeda et al., 1985, *Nature* 314:452-454) by splicing the genes from a mouse antibody molecule specific for an oligosaccharide together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. Such human or humanized chimeric antibodies are preferred for use in therapy of human diseases or disorders, since the human or humanized antibodies are much less likely than xenogenic antibodies to induce an immune response, in particular an allergic response, themselves. According to the invention, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce oligosaccharide-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989, *Science* 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for an oligosaccharide, or its derivatives, or analogs.

Antibody fragments which contain the idiotype of the antibody molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.

In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g., radioimmunoassay, ELISA (enzyme-linked immunosorbant assay), "sandwich" immunoassays,

10 immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, *in situ* immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. For example, to select antibodies which recognize a specific oligosaccharide, one may assay generated hybridomas for a product which binds to an oligosaccharide containing such epitope. For selection of an antibody specific to an oligosaccharide from a particular species or strain of *Neisseria*, one can select on the basis of positive binding with oligosaccharide expressed by or isolated from cells of that species or strain.

The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the oligosaccharide, e.g., for Western blotting, imaging oligosaccharide *in situ*, measuring levels thereof in appropriate physiological samples, etc.

Diagnosis of infection with a Gram positive bacterium can use any immunoassay format known in the art, as desired. The antibodies can be labeled for detection *in vitro*, e.g., with labels such as enzymes, fluorophores, chromophores, radioisotopes, dyes, colloidal gold, latex particles, and chemiluminescent agents.

5 Alternatively, the antibodies can be labeled for detection *in vivo*, e.g., with radioisotopes (preferably technetium or iodine); magnetic resonance shift reagents (such as gadolinium and manganese); or radio-opaque reagents.

Alternatively, the nucleic acids and sequences thereof of the invention can be used in the diagnosis of infection with *Neisseria*, in particular, to identify a particular 10 strain, or to determine which, if any, of the glycosyltransferase genes are mutated. For example, the *lgt* genes or hybridizable fragments thereof can be used for *in situ* hybridization with a sample from a subject suspected of harboring an infection of *Neisseria* bacteria. In another embodiment, specific gene segments of a 15 *Neisseria* can be identified using PCR amplification with probes based on the *lgt* genes of the invention. In one aspect of the invention, the hybridization with a probe or with the PCR primers can be performed under stringent conditions, or with a sequence specific for a unique strain or a limited number of strains of the bacterium, or both, thus allowing for diagnosis of infection with that particular 20 strain (or strains). Alternatively, the hybridization can be under less stringent conditions, or the sequence may be homologous in any or all strains of a bacterium, thus allowing for diagnosis of infection with that species.

The present invention will be better understood from a review of the following illustrative description presenting the details of the constructs and procedures that were followed in its development and validation.

25

EXAMPLE

This Example describes a locus in *Neisseria gonorrhoeae* strain F62 containing five genes. Four of the genes are responsible for the sequential addition of the

GalNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4 to the substrate Glc β 1 \rightarrow 4Hep \rightarrow R of the inner core region (Yamasaki et al., 1991, Biochemistry 30:10566). The fifth gene is involved with the addition of the α -linked galactose residue in the biosynthesis of the alternative LOS structure Gal α 1 \rightarrow 4Gal β 1 \rightarrow 4Glc β 1 \rightarrow 4Hep \rightarrow R

5 (John et al., 1991, J. Biol. Chem. 266:19303). The DNA sequence analysis revealed that the first, third and fourth reading frames contained poly-G tracts which in strain F62 were respectively 17, 10 and 11 bp. Thus, three of the LOS biosynthetic enzymes are potentially susceptible to premature termination by reading-frame changes, as has been reported for the gonococcal *pilC* genes

10 (Jonsson et al., 1991, EMBO J. 10:477; Rudel et al., 1992, Molec. Microbiol. 6:3439). It is likely that these structural features are responsible for the high-frequency genetic variation of gonococcal LOS (Schneider et al., 1988, Infect. Immun. 56:942).

Materials and Methods

15 *Reagents and chemicals.* Most laboratory chemicals were obtained from Sigma Chemical Co (St. Louis, MO). Restriction enzymes were purchased from New England Biolabs (Beverly, MA).

Media and growth conditions. *E. coli* strains were grown in solid or liquid LB medium (Sambrook et al., 1989, Cold Spring Harbor Laboratory Press, Cold

20 Spring Harbor); antibiotics were added as applicable. Carbenicillin was used at 50 μ g/ml and erythromycin at 200 μ g/ml. *Neisseria gonorrhoeae* strain F62 was grown on GC agar (Swanson, 1978, Infect. Immun. 19:320) or GC agar containing 2 μ g/ml erythromycin. For isolation of LOS or genomic DNA, gonococci were grown in 1.5% proteose peptone broth (Difco Laboratories, Detroit MI), 30 mM phosphate, 8.5 mM NaCl supplemented with 1% isovitalex (Becton Dickinson Microbiology Systems, Cockeysville, MD).

Recombinant DNA methods. Plasmids were purified using either Qiagen columns or the QIAprep spin columns obtained from Qiagen Inc. (Chatsworth, CA). Digestion with restriction enzymes, gel electrophoresis, ligations with T4 DNA polymerase and transformation of *E. coli* were done according to Sambrook et al. (Sambrook et al., 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor). Southern hybridization was performed on Hybond N+ membranes Amersham Co. (Arlington Heights, IL) with DNA labeled using the ECL kit from Amersham Co. Genomic DNA was isolated as described by Moxon et al. (Moxon et al., 1984, J. Clin. Invest. 73:298).

10 A gene bank of *Neisseria gonorrhoeae* strain F62 genomic DNA was constructed by ligating ca 20 kb fragments obtained by incomplete digestion with *Sau3A* into *BamHI/EcoRI* digested λ2001 (Karn et al., 1984, Gene 32:217). The phage library was screened by hybridization with random-primer-labeled plasmid pR10PI, and 5 clones were isolated by plaque purification. The phage from these 15 clones were purified by sedimentation followed by flotation on CsCl (Davis et al., 1980, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY), and the DNA was isolated. From one of these clones, two *ClaI* fragments of 4.9 and 3.4 kb were isolated by gel electrophoresis and recovery with Geneclean II (BIO 101 Inc., La Jolla, CA). These were ligated into *ClaI* cut pBluescript II SK- from 20 Stratagene (La Jolla, CA) and called p4900 and p3400 respectively. p4900 contained a *PstI* site in the insert and was subdivided into two clones containing inserts of 2.1 and 2.8 kb. The clone containing the 2.8 kb insert was called pPstCla. The inserts in p3400 and pPstCla were sequenced by the chain termination method (Sanger et al., 1977, Proc. Natl. Acad. Sci. USA 74:5463) 25 using Sequenase II, (United States Biochemical Co., Cleveland, OH). All of the sequence presented in Figure 2 was completed in both directions.

The insertion and deletions shown in Figure 6 were constructed as follows. I1, I3, Δ1 and Δ2 used plasmid pPstCla cut respectively with *BsaBI*, *Ascl*, *StyI* and double cut with *StyI* and *BsaBI*. I2 and Δ3 used plasmid p3400 cut with *AgeI* or

StyI. The complete locus was assembled by cloning the *ClaI* - *Apal* fragment from p3400 into pPst*Cla* cut with *ClaI* and *Apal*, and the plasmid was called pLOS5. Deletions $\Delta 4$ and $\Delta 5$ were constructed using pLOS5 and digestion with *StyI* and *BbsI* or with *StyI* alone. In all instances (except digestion with *BsaBI*) the cut 5 plasmids were treated with the Klenow fragment of *E. coli* DNA polymerase to blunt the ends, and *ermC'* (erythromycin resistance marker) was inserted. The *ermC'* gene was isolated from plasmid pIM13 (Projan et al., 1987, J. Bacteriol. 169:5131) as a *ClaI* - *HindIII* fragment and cloned into the same sites in plasmid pHSS6 (Seifert et al., 1986, Proc. Natl. Acad. Sci. USA 83:735). From this 10 plasmid it was excised as a *NotI* fragment, the ends blunted by treatment with Klenow fragment of DNA polymerase, purified by gel electrophoresis and recovery with Geneclean II.

Transformation of pilated *Neisseria gonorrhoeae* strain F62 was performed with plasmids isolated from *E. coli* (Klugman et al., 1989, Infect. Immun. 57:2066) 15 and the transformants selected on GC agar (Swanson, 1978, Infect. Immun. 19:320) containing 2 μ g/ml erythromycin. The fidelity of the genomic alteration of each of the gonococcal transformants was verified by sequencing the upstream and downstream junctions of the *ermC'* gene in their genomic DNA using a PCR technique. Two 5' biotinylated primers, GCCGAGAAA^{ACTATTGGTGGA} 20 (SEQ. ID. NO:9) and AAAACATGCAGGAATTGACGAT (SEQ. ID. NO:10), were synthesized: these were based on the *ermC'* sequence near its upstream and its downstream end respectively. The primers were designed such that their 3' ends pointed outward from the *ermC'* gene. Each of these primers was used together with a suitable primer matching the sequence of the LOS locus near the 25 putative insertion. PCR was performed according the instructions supplied with the GeneAmp PCR Reagent Kit from Perkin Elmer (Branchburg, NJ) using 25 cycles. In all instances the expected size product was obtained. The DNA sequence of these products was determined by purifying the PCR product on magnetic streptavidin beads from Dynal, Inc. (Lake Success, NY) and sequencing 30 with the Sequenase II kit according to a protocol provided by Dynal, Inc., based

on the method developed by Hultman et al (Hultman et al., 1989, Nucleic Acids Res. 17:4937). The sequences were analyzed by computer programs in the GCG package of Genetics Computer Group, Inc. (Madison, WI).

Immunological methods. Monoclonal antibodies 17-1-L1 (L1), 9-2-L378 (L3), 2-5 1-L8 (L8) were obtained as filtered ascites fluids. Antibody 1-1-M was obtained as ascites fluid and 3F11 and 4C4 were obtained as tissue culture supernatants. LOS was extracted from each of the gonococcal mutants by the hot phenol-water method (Westphal and Jann, 1965, Academic Press, New York 83-91) and purified as described (Johnston et al., 1976, J. Exp. Med. 143:741). The LOS 10 was diluted to 200 µg/ml in the Western blot buffer described by Towbin et al. (Towbin et al., 1979, Proc. Natl. Acad. Sci. USA 76:4350), and 1.5 µl aliquots were spotted on Immobilon-P membrane from Millipore Corp (Bedford, MA) that was lying on 3MM Whatman filter paper (Whatman Ltd., Maidstone, England) soaked in the blotting buffer. The spots were allowed to absorb into the 15 membrane over a period of 2 min and the strips were placed in blocking buffer for at least 60 min. The blocking buffer consisted of 3% gelatin dissolved in 150 mM NaCl, 10 mM Tris-HCl 10 mM pH 7.5, 5 mM MgCl₂, 0.02% NaN₃. The strips were washed thrice in the same buffer containing 1% gelatin. The strips were treated for 2 h with monoclonal antibodies diluted in blocking buffer. The 20 antibodies available as ascites fluids were diluted 1/1000, antibodies available as tissue culture supernatants 1/10. The strips were washed, incubated for 60 min with a 1/1000 dilution of phosphatase-conjugated anti-IgG,IgA,IgM from Cappel (Organon Teknika Co., West Chester, PA), washed and stained as described previously (Blake et al., 1984, Analyt. Biochem. 136:175).

25 *Gel electrophoresis.* Gel electrophoresis of LOS samples was performed as described by Lesse et al (Less et al., 1990, J. Immunol. Meth. 126:109) and the gels silver stained (Hitchcock and Brown, 1983, J. Bacteriol. 154:269).

Results

Cloning of the LOS Locus. During attempts to isolate the porin gene of *Neisseria gonorrhoeae*, pBR322 clones containing a 4.9 kb *Cla*I fragment that reacted by colony blots with a rabbit antiserum to purified porin were repeatedly isolated.

5 An immunoreactive subclone, pR10PI, consisting of a 1305 bp *Rsa*I-*Cla*I fragment was derived and its DNA sequence was determined. This sequence had homology to a gene isolated from *Haemophilus influenzae* called *lex-1* (Cope et al., 1991, Molec. Microbiol. 5:1113) or *lic2A* (High et al., 1993, Molec. Microbiol. 9:1275) that is known to be involved in LPS synthesis of that species. Using subclone

10 pR10PI as a probe, Southern blots of *Neisseria gonorrhoeae* genomic DNA digested with *Cla*I revealed hybridization with two fragments, 4.9 and 3.4 kb. However, digestion with some other restriction enzymes gave rise to only a single band. Notably, digestion with *Bfa*I gave rise to a single band of 4.1 kb, suggesting that the two copies were closely linked (data not shown).

15 A λ2001 bank of *Neisseria gonorrhoeae* strain F62 DNA was screened by hybridization with pR10PI and 5 clones were isolated. One of these clones, when digested with either *Cla*I or *Bfa*I and examined by Southern hybridization using pR10PI as the probe, gave rise to a pattern identical to that seen with genomic DNA. The appropriate *Cla*I fragments of this λ2001 clone were isolated and

20 cloned into the *Cla*I site of pBluescript II SK-. The entire sequence of the 3400 *Cla*I fragment was determined. Mapping of the clone containing the 4900 bp *Cla*I fragment indicated that there was a single *Pst*I site in the clone about 2.8 kb from one side, allowing the clone to be divided into two subclones. Partial sequence of the ends of the 2.1 kb subclone indicated that it contained a coding frame

25 homologous to the *E. coli* COOH-terminal portion of the α subunit of glycyl-tRNA synthetase (*glyS*) and the majority of the β subunit of this gene (Webster et al., 1983, J. Biol. Chem. 258:10637). The predicted length of DNA needed to match the *E. coli* sequence was present; this clone was not examined further.

DNA Sequence of the LOS Locus. A summary of the features found by sequencing the two clones is illustrated in Figure 2. Following the *glyS* gene were found five closely spaced open reading frames. The last frame has 46 bp downstream of the termination codon a sequence typical of a rho independent termination signal.

5 Subsequently, there is an area of ca 100 bp that has striking homology to the IS1106 neisserial insertion sequence (Knight et al., 1992, *Molec. Microbiol.* 6:1565). Further elucidation of the nature of this locus, presented below, showed the five open reading frames code for LOS glycosyl transferases and hence they have been named *lgtA* - *lgtE*.

10 Searches for internal homology within this locus indicates that the DNA coding for the first two genes (*lgtA*, *lgtB*) is repeated as the fourth and fifth genes (*lgtD*, *lgtE*) and that interposed is an additional open reading frame, *lgtC*. This is in keeping with the data obtained by Southern hybridization presented above, in which pR10PI probe containing the *lgtB* and a small portion of the *lgtC* gene

15 hybridized with two *Cla*I fragments, but with only one *Bfa*I fragment (see positions of the *Bfa*I sites in the LOS locus in Figure 2). In more detail, 16 bp following the stop codon of the tRNA synthetase (*glyS*) is the beginning of a stem loop structure followed closely by a consensus ribosome binding site (rbs), and within 6 bp is a TTG believed to be the initiation codon of *lgtA*. 2871 bp

20 downstream from the beginning of the stem loop (closely following the stop codon of *lgtC*) there is an almost perfect repeat of the stem loop structure, the rbs, and the TTG initiation codon of *lgtD*, with the downstream sequence strongly homologous for about 500 bp. The sequences then diverge to some extent. However, at the beginning of *lgtB* and *lgtE* the homology again becomes nearly

25 perfect for ca 200 bases to then diverge toward the latter part of the orfs. The similarity of the homologous proteins is illustrated in Figures 3 and 4. These comparisons, demonstrate the near-perfect conservation of the primary structure in the N-terminal portions of the molecules with increasing divergence toward the COOH-termini of the proteins.

The *lgtC* sequence interposed between the repeated portions of the locus is not repeated within the locus or in the *Neisseria gonorrhoeae* genome (data not shown). It appears to be homologous to *E. coli rfaI* or *rfaJ* genes, which are very closely related genes that serve as glucosyl transferases in core LPS biosynthesis

5 (Pradel et al., 1992, J. Bacteriol. 174:4736). The similarity of *rfaI* with *lgtC* is illustrated in Figure 5.

It was found that three of these genes contained within their coding frame runs of guanosines coding for stretches of glycines (see Figure 2). These poly-G regions were found in *lgtA* (17 bp), *lgtC* (10 bp) and *lgtD* (11 bp); in each case the

10 number G residues was one that maintained an intact reading frame (see Figures 3 and 5). In each of the three genes a change of 1 or 2 G bases would cause premature termination of the transcript.

LOS phenotype of Neisseria gonorrhoea F62 with deletions of the LOS locus. In order to define the function of the *lgt* genes, insertions or deletions of the LOS

15 locus were constructed in plasmids propagated in *E. coli*. The insertions or deletions in each case were marked with the *ermC'* gene, which is an excellent selective marker in *Neisseria gonorrhoeae* (Klugman et al., 1989, Infect. Immun. 57:2066). The constructions are summarized in Figure 6. I1, I2 and I3 refer to insertions of the *ermC'* marker into, respectively, a *BsaBI*, *AgeI* and *AscI* site.

20 Similarly, the deletions were constructed by excising portions of the plasmids and substituting the erythromycin marker. The open arrows indicate the gene or genes disrupted. Each of these plasmids was used to transform *Neisseria gonorrhoeae* strain F62 and transformants were selected on erythromycin-containing plates. The fidelity of the genomic alteration of a prototype of each of the gonococcal

25 transformants was verified by sequencing the upstream and downstream junction of the *ermC'* gene. To simplify the nomenclature in this report the gonococcal mutants have been given the same names used to identify the plasmid constructs in Figure 6.

The LOS of the mutants were examined by SDS-PAGE and compared to the LOS of strain 1291e. This strain was originally isolated by Dudas and Apicella (Dudas and Apicella, 1988, Infect. Immun. 56:499) as a pyocin-resistant mutant of strain 1291 wild type and has been extensively characterized both chemically and

5 genetically. Chemical analysis has shown that this mutant lacks completely the lacto-N-neotetraose substitution on heptose 1 (John et al., 1991, J. Biol. Chem. 266:19303). The genetic basis of this mutant has been defined (Zhou et al., 1994, J. Biol. Chem. 269:11162; Sandlin and Stein, 1994, J. Bacteriol. 176:2930); it is a mutation of the *pgm* gene coding for phosphoglucomutase. This mutation

10 prohibits the synthesis of UDP-glucose and hence the addition of glucose to the heptose. As seen in Figure 7, the parental wild type F62 strain gives rise to two major LOS bands; their appearance is indistinguishable from SDS-PAGE patterns previously published by other workers (Schneider et al., 1985, Amer. Soc. Microbiology, Washington 400-405). The mutants are arranged on the gel

15 according to the size of the major band that they contain. The size decreases from the top band of the F62 wt LOS in four clear steps to the size of the LOS of Δ4 or I2. Since the I2 mutant (with an insertion into *lgtE*, the last gene in the locus) has the same phenotype as Δ4 (which has a complete deletion of the locus), it suggests that the *lgtE* product performs the first biosynthetic step. Thus, the enzymes

20 encoded by *lgtA-D*, although intact, do not have a substrate to act upon. Mutant Δ5 (a deletion of the locus with the exception of *lgtE*) gives rise to a LOS that is one step larger, supporting the idea that this gene accounts for the initial biosynthetic step. Note that the LOS of both I2 and Δ4 mutants is perceptibly larger than the LOS of strain 1291e which is known to be unable to add glucose,

25 the first residue in the lacto-N-neotetraose chain. These data suggest that *lgtE* encodes the galactosyl transferase enzyme which adds the first galactose of the lacto-N-neotetraose.

The LOS preparations were also studied using a dot blot technique for their reactivity with monoclonal antibodies. The monoclonal antibodies employed and

30 their reported specificities are shown in Figure 1. The reactions observed with the

LOS obtained from the parental strain and the mutants are summarized in Figure 8. The reactivity of the parental F62 with 1-1-M, 3F11 and L8 was as reported previously by Mandrell et al (Mandrell et al., 1985, Amer. Soc. Microbiology, Washington 379-384) and by Yamasaki et al (Yamasaki et al., 1991, Mol.

5 Immunol. 28:1233). Mutants $\Delta 4$ and I2 fail to react with any of the antibodies. However, $\Delta 5$ gives a strong reaction with antibodies 4C4 and L8, indicating that the first galactose residue is present. This is in keeping with the SDS-PAGE results (see fig 6) and supports the role of *lgtE* as the galactosyl transferase. It also indicates that deletions upstream of *lgtE* do not significantly inactivate its
10 function by polar effects. The LOS of F62 wt parent has strong reactivity with L3 and weak reactivity with 3F11. It is known that reactivity 3F11 is occluded by the addition of the GalNAc residue (Schneider et al., J. Exp. Med. 174:1601); this is not the case with the L3 antibody. The wt LOS reacts with 1-1-M, the antibody reactive when the terminal GalNAc residue is present. The reactivity with 1-1-M
15 is lost in $\Delta 3$ which has a deletion only in *lgtD*. This suggest that this gene encodes the GalNAc transferase.

The reactivity with antibody L1 (specific for the alternative LOS structure capped with an $\alpha 1 \rightarrow 4$ Gal) is not seen in wt LOS, is absent in I1, and all deletions which affect *lgtC*. The reactivity is strongest in $\Delta 1$, which has a deletion of *lgtA* only.

20 Note that this mutant also has lost reactivity with 3F11 and L3. These two findings suggest that *lgtA* codes for the GlcNAc transferase, and when this residue is not added, the incomplete chain is a substrate for the action of *lgtC* to produce the alternative LOS structure. Note that the sizes of the LOS products seen in Figure 7 are in accord with the immunological data. This conclusion suggests that
25 *lgtC* encodes the α -Gal transferase. This is further supported by the weak reactivity of mutant $\Delta 3$ with antibody L1. Mutant $\Delta 3$ has a deletion of *lgtD* and fails to add the terminal GalNAc, allowing the α -Gal transferase to modify the lacto-N-neotetraose group to produce a P_i-like globoside (Mandrell, 1992, Infect. Immun. 60:3017). Mutant I3 (with inactive *lgtB*) has lost reactivity with 1-1-M,
30 3F11 and L1, and remains only weakly reactive with L3. Together with the size

of the product, these observations suggest that *lgtB* encodes the galactosyl transferase adding Gal β 1-4 to the GlcNAc residue. *Ricinus* lectin RCA-I is specific for terminal galactose in β linkage (Nicolson and Blaustein, 1972, Biochim. Biophys. Acta 266:543; Lin and Li, 1980, Eur. J. Biochem. 105:453) and was used to confirm the presence of this structure on the LOS preparations. Using ELISA tests it was found that wild type, $\Delta 3$, $\Delta 2$ and $\Delta 5$ LOS, expected to bear a terminal β Gal, bound the lectin (see Figure 7), while $\Delta 4$, I2, $\Delta 1$ and I3 were unreactive (data not shown).

Discussion

- 10 A locus containing 5 open reading frames has been cloned. The effect of eight defined mutations within this locus on the size and serological reactivity of the LOS produced by gonococcal transformants suggests that these genes are the glycosyl transferases responsible for the biosynthesis of most of the lacto-N-neotetraose chain. The data obtained allow an identification of the function of
- 15 each of these genes. It is noteworthy that *lgtB* and *lgtE*, which are structurally very closely related, also perform an apparently very similar biosynthetic task, i.e. the addition of Gal β 1-4 to GlcNAc or Glc, respectively. Similarly, the closely related *lgtA* and *lgtD* add GalNAc or GlcNAc β 1-3, respectively, to a Gal residue. *lgtC*, which is unrelated to the other genes in the locus, is responsible for
- 20 the addition of a Gal α 1-4.

The DNA sequence showed that three of the genes (*lgtA*, *lgtC* and *lgtD*) contain tracts of guanosines which code for glycine residues in the proteins. These provide a potential mechanism for high-frequency variation of expression of these genes. Slippage in such poly-G tracts is well documented to control the expression of the gonococcal *pilC* genes, with resultant effects on pilus adhesiveness to human epithelial cells (Rudel et al., 1992, Molec. Microbiol. 6:3439). In strain F62, the numbers of bases in each of the three poly-G regions were such that the proteins

are in frame, and this is in keeping with the ability of F62 wild type to produce a complete LOS including the addition of the terminal GalNAc.

Three aspects of LOS biosynthesis appear potentially to be subject to high frequency variation. The first is the addition of the terminal GalNAc (*lgtD*). This 5 would cause an alteration of reactivity with monoclonal antibody 1-1-M, and this phase variation has been reported by van Putten (Van Putten, 1993, EMBO J. 12:4043). Similarly, a change in *lgtA* would cause the failure of the addition of GlcNAc to the growing chain and truncate the LOS at the β -lactosyl level. This is a very common form of LOS in gonococci with a 3.6 kilodalton molecule, which 10 confers resistance to the bactericidal effect of normal human serum (Schneider et al., 1985, Infect. Immun. 50:672). It is tempting to speculate that the *in vitro* variation between variant A and C of MS11_{mk} from the β -lactosyl chain to a complete LOS (which had a selective advantage *in vivo* in the volunteers) could be explained by regaining functional expression, of the GlcNAc transferase *lgtA*. 15 Finally, the variable addition of α 1-4Gal to either the β -lactosyl (p^k-like globotriose) or the lacto-N-neotetraose group (P₁-like globoside) (Mandrell, 1992, Infect. Immun. 60:3017) would be under the control of the expression of *lgtC*. The activity of the *lgtC* transferase appears to compete poorly with the other transferases for precursor and its activity is evident only if either *lgtA* or *lgtD* are 20 silent. For the Gal α 1-4Gal β 1-4Glc trisaccharide to be synthesized the GlcNAc transferase *lgtA* must be inactive and for expression of the P₁-like globoside Gal α 1-4Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc the GalNAc transferase *lgtD* must be silent.

Comparable high frequency antigenic variation of *Haemophilus influenzae* LOS has 25 also been noted and has been attributed to changes in translational frame caused by shifts in the number of CAAT repeats in two separate loci, *lic1* (Weiser et al., 1989, Cell 59:657) and *lic2* (High et al., 1993, Molec. Microbiol. 9:1275). Shifts allowing the expression of the *lic2* gene are correlated with the expression of an epitope with the structure Gal α 1-4Gal β 1-. Since the *lic2* gene is homologous to

lgtB and *lgtE* the galactosyl transferases which link Gal β 1-4 to respectively Glc or GlcNAc, it is likely that this is its function in *Haemophilus influenzae* LOS synthesis. It is remarkable that while both these mucosal pathogens have evolved frame shift mechanisms to cause antigenic variation of the LOS, that the 5 gonococcal homologs of *lic2*, (*lgtB* and *lgtE*) are not the ones that contain poly-G tracts.

While the frame-shift mechanisms discussed above are suited for on/off regulation of gene expression, the structure of the locus also lends itself to more subtle regulation of the level of expression of the genes. It has been demonstrated that 10 growth rate affects the molecular weight distribution and antigenic character LOS species produced (Morse et al., 1983, Infect. Immun. 41:74). While I have not determined the size of the RNA transcripts it is very likely that *lgtA*, *lgtB* and *lgtC* (in the instance where the poly-G tracts are such that the coding frame is maintained) are transcribed together. The termination codon of *lgtA* and the 15 initiation codon of *lgtB* in fact overlap, and the distance between the TAA of *lgtB* and the ATG of *lgtC* is only 11 bp. Similarly, the stop codon of *lgtD* and the start codon of *lgtE* are separated by only 18 bp. Yet the organization is such that if any of the three genes subject to phase variation are in the off configuration, transcription is able to reinitiate effectively at the beginning of the next gene. This 20 ability to reinitiate transcription was clearly seen with the mutations constructed in this study.

The correlation of LOS structure with function is still in its early stages. The major advances in the field have been the development of an understanding of the structure of the molecules and the ability to relate this, often unambiguously, to 25 the reactivity with a number of well-characterized monoclonal antibodies. Added to this is the realization that in the *in vivo* environment, which provides CMP-NANA, the organism may or may not sialylate the LOS, depending whether the LOS synthesized is a competent acceptor structure. It is well known that sialylation induces a serum-resistant state in many strains. However, the effect of

sialylation in local infection is not as well studied. van Putten has shown that sialylation of LOS has a marked inhibitory effect on epithelial cell invasion, without apparently greatly altering adhesion (Van Putten, 1993, EMBO J. 12:4043). His studies suggest that in the mucosal infection, LOS structures that 5 cannot be sialylated may be important for efficient cell invasion. In the context of this report, such structures could be achieved either by the efficient addition of the terminal GalNAc or by shortening the LOS chain by silencing the GlcNAc transferase. The correlation of LOS chemistry with biological reaction has been complicated by the leakiness of the existing LOS mutants isolated by pyocin 10 selection (Dudas and Apicella, 1988, Infect. Immun. 56:499; Sandlin et al., 1993, Infect. Immun. 61:3360). This is in fact exemplified with mutant 1291e which shows in addition to the major low molecular weight band, an additional higher band (see Figure 7). The new insight provided into the genetics of the biosynthesis of gonococcal LOS will allow construction of mutants that are not 15 leaky. For instance, $\Delta 4$ and $\Delta 5$ should be stable mutants since they no longer contain genes with poly-G tracts. The expression of the genes containing the poly-G tracts could be stabilized by engineering the areas so that glycines are encoded by other codons.

The present invention is not to be limited in scope by the specific embodiments 20 described herein, since such embodiments are intended as but single illustrations of one aspect of the invention and any functionally equivalent embodiments are within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such 25 modifications are intended to fall within the scope of the appended claims. It is also to be understood that all base pair sizes given for nucleotides are approximate and are used for the purpose of description. Various references are cited herein, the disclosures of which are incorporated by reference herein in their entirety.

WHAT IS CLAIMED IS:

- 1 1. A purified nucleic acid that is hybridizable under moderately stringent conditions to a nucleic acid having a nucleotide sequence corresponding to or complementary to the nucleotide sequence shown in Figure 2 (SEQ ID NO:1).
- 1 2. The nucleic acid of Claim 1 that is hybridizable under moderately stringent conditions to a nucleic acid having a nucleotide sequence corresponding to or complementary to a portion of the nucleotide sequence shown in Figure 2 (SEQ ID NO:1) that encodes a functionally active glycosyltransferase.
- 1 3. The nucleic acid of Claim 2 that encodes a functionally active glycosyltransferase.
- 1 4. The nucleic acid of Claim 1 that has a nucleotide sequence corresponding to or complementary to a portion of the nucleotide sequence shown in Figure 2 (SEQ ID NO:1) that encodes a functionally active glycosyltransferase.
- 1 5. The nucleic acid of Claim 4 that encodes a functionally active glycosyltransferase.
- 1 6. The nucleic acid of Claim 1 that has a nucleotide sequence corresponding to or complementary to the nucleotide sequence shown in Figure 2 (SEQ ID NO:1).
- 1 7. The nucleic acid of Claim 3, wherein the functionally active glycosyltransferase catalyzes a reaction selected from the group consisting of:
 - 3 a) adding Gal $\beta 1 \rightarrow 4$ to GlcNAc or Glc;
 - 4 b) adding GalNAc or GlcNAc $\beta 1 \rightarrow 3$ to Gal; and
 - 5 c) adding Gal $\alpha 1 \rightarrow 4$ to Gal.

1 8. The nucleic acid of Claim 3 which encodes a glycosyltransferase having an
2 amino acid sequence of SEQ ID NO:3.

1 9. The nucleic acid of Claim 3 which encodes a glycosyltransferase having an
2 amino acid sequence of SEQ ID NO:8.

1 10. The nucleic acid of Claim 3 which encodes a glycosyltransferase having an
2 amino acid sequence of SEQ ID NO:4.

1 11. The nucleic acid of Claim 3 which encodes a glycosyltransferase having an
2 amino acid sequence of SEQ ID NO:5.

1 12. The nucleic acid of Claim 3 which encodes a glycosyltransferase having an
2 amino acid sequence of SEQ ID NO:6.

1 13. An expression vector comprising the nucleic acid of Claim 3 operatively
2 associated with an expression control sequence.

1 14. A recombinant host cell transformed with the expression vector of Claim
2 13.

1 15. A method for producing a glycosyltransferase comprising:
2 a) culturing the recombinant host cell of Claim 14 under conditions
3 that allow expression of the glycosyltransferase; and
4 b) recovering the expressed glycosyltransferase.

1 16. A glycosyltransferase having an amino acid sequence of SEQ ID NO:3, or
2 a functionally active fragment thereof.

1 17. A glycosyltransferase having an amino acid sequence of SEQ ID NO:8, or
2 a functionally active fragment thereof.

- 1 18. A glycosyltransferase having an amino acid sequence of SEQ ID NO:4, or
- 2 a functionally active fragment thereof.

- 1 19. A glycosyltransferase having an amino acid sequence of SEQ ID NO:5, or
- 2 a functionally active fragment thereof.

- 1 20. A glycosyltransferase having an amino acid sequence of SEQ ID NO:6, or
- 2 a functionally active fragment thereof.

- 1 21. A composition comprising a glycosyltransferase conjugated to a solid phase
- 2 support, wherein the glycosyltransferase is selected from the group consisting of:
 - 3 a) a glycosyltransferase having an amino acid sequence of SEQ ID
 - 4 NO:3, or a functionally active fragment thereof;
 - 5 b) a glycosyltransferase having an amino acid sequence of SEQ ID
 - 6 NO:8, or a functionally active fragment thereof;
 - 7 c) a glycosyltransferase having an amino acid sequence of SEQ ID
 - 8 NO:4, or a functionally active fragment thereof;
 - 9 d) a glycosyltransferase having an amino acid sequence of SEQ ID
 - 10 NO:5, or a functionally active fragment thereof; and
 - 11 e) a glycosyltransferase having an amino acid sequence of SEQ ID
 - 12 NO:6, or a functionally active fragment thereof.

- 1 22. A method for adding GalNAc or GlcNAc β 1-3 to Gal, comprising
- 2 contacting a reaction mixture comprising an activated GalNAc or GlcNAc to an
- 3 acceptor moiety comprising a Gal residue in the presence of the
- 4 glycosyltransferase of Claim 16.

- 1 23. A method for adding Gal β 1-4 to GlcNAc or Glc, comprising contacting a
- 2 reaction mixture comprising an activated Gal to an acceptor moiety comprising a
- 3 GlcNAc or Glc residue in the presence of the glycosyltransferase of Claim 17.

- 1 24. A method for adding Gal $\alpha 1 \rightarrow 4$ to Gal, comprising contacting a reaction
- 2 mixture comprising an activated Gal to an acceptor moiety comprising a Gal
- 3 residue in the presence of the glycosyltransferase of Claim 18.

- 1 25. A method for adding GalNAc or GlcNAc $\beta 1 \rightarrow 3$ to Gal, comprising
- 2 contacting a reaction mixture comprising an activated GalNAc or GlcNAc to an
- 3 acceptor moiety comprising a Gal residue in the presence of the
- 4 glycosyltransferase of Claim 19.

- 1 26. A method for adding Gal $\beta 1 \rightarrow 4$ to GlcNAc or Glc, comprising contacting a
- 2 reaction mixture comprising an activated Gal to an acceptor moiety comprising a
- 3 GlcNAc or Glc residue in the presence of the glycosyltransferase of Claim 20.

- 1 27. A method for preparing an oligosaccharide having the structure
- 2 Gal $\alpha 1 \rightarrow 4$ Gal $\beta 1 \rightarrow 4$ Glc, which comprises sequentially performing the steps of:
- 3 a) contacting a reaction mixture comprising an activated Gal to an
- 4 acceptor moiety comprising a Glc residue in the presence of a
- 5 glycosyltransferase having an amino acid sequence of SEQ ID NO:6, or a
- 6 functionally active fragment thereof; and
- 7 b) contacting a reaction mixture comprising an activated Gal to the
- 8 acceptor moiety comprising Gal $\beta 1 \rightarrow 4$ Glc in the presence of a
- 9 glycosyltransferase having an amino acid sequence of SEQ ID NO:4, or a
- 10 functionally active fragment thereof.

- 1 28. A method for preparing an oligosaccharide having the structure
- 2 Gal $\beta 1 \rightarrow 4$ Glc, which comprises contacting a reaction mixture comprising an
- 3 activated Gal to an acceptor moiety comprising a Glc residue in the presence of
- 4 the glycosyltransferase of Claim 20.

- 1 29. A method for preparing an oligosaccharide having the structure
- 2 GlcNAc $\beta 1 \rightarrow 3$ Gal $\beta 1 \rightarrow 4$ Glc, which comprises contacting a reaction mixture

3 comprising an activated GlcNAc to an acceptor moiety comprising a Gal β 1 \rightarrow 4Glc
4 residue in the presence of the glycosyltransferase of Claim 16.

1 30. A method for preparing an oligosaccharide having the structure
2 Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc, which comprises contacting a reaction mixture
3 comprising an activated Gal to an acceptor moiety comprising a
4 GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc residue in the presence of the glycosyltransferase of
5 Claim 17.

1 31. A method for preparing an oligosaccharide having the structure
2 GalNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc, which comprises contacting a
3 reaction mixture comprising an activated GalNAc to an acceptor moiety
4 comprising a Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc residue in the presence of the
5 glycosyltransferase of Claim 19.

1 32. A method for preparing an oligosaccharide having the structure
2 GalNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc, which comprises sequentially
3 performing the steps of:
4 a) contacting a reaction mixture comprising an activated Gal to an
5 acceptor moiety comprising a Glc residue in the presence of a
6 glycosyltransferase having an amino acid sequence of SEQ ID NO: 6, or a
7 functionally active fragment thereof;
8 b) contacting a reaction mixture comprising an activated GlcNAc to the
9 acceptor moiety comprising a Gal β 1 \rightarrow 4Glc residue in the presence of a
10 glycosyltransferase having an amino acid sequence of SEQ ID NO:3, or a
11 functionally active fragment thereof;
12 c) contacting a reaction mixture comprising an activated Gal to the
13 acceptor moiety comprising a GlcNAc β 1 \rightarrow 3Gal β 1 \rightarrow 4Glc residue in the
14 presence of a glycosyltransferase having an amino acid of SEQ ID NO:8;
15 and

16 d) contacting a reaction mixture comprising an activated GalNAc to the
17 acceptor moiety comprising a $\text{Gal}\beta 1\rightarrow 4\text{GlcNAc}\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 4\text{Glc}$ residue in
18 the presence of a glycosyltransferase having an amino acid sequence of
19 SEQ ID NO:5, or a functionally active fragment thereof.


1 33. A method for preparing an oligosaccharide having the structure
2 $\text{Gal}\beta 1\rightarrow 4\text{GlcNAc}\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 4\text{Glc}$, which comprises sequentially performing the
3 steps of:

4 a) contacting a reaction mixture comprising an activated Gal to an
5 acceptor moiety comprising a Glc residue in the presence of a
6 glycosyltransferase having an amino acid sequence of SEQ ID NO: 6, or a
7 functionally active fragment thereof;

8 b) contacting a reaction mixture comprising an activated GlcNAc to the
9 acceptor moiety comprising a $\text{Gal}\beta 1\rightarrow 4\text{Glc}$ residue in the presence of a
10 glycosyltransferase having an amino acid sequence of SEQ ID NO:3, or a
11 functionally active fragment thereof; and

12 c) contacting a reaction mixture comprising an activated Gal to the
13 acceptor moiety comprising a $\text{GlcNAc}\beta 1\rightarrow 3\text{Gal}\beta 1\rightarrow 4\text{Glc}$ residue in the
14 presence of a glycosyltransferase having an amino acid of SEQ ID NO:8.

Lacto-N-neotetraose



1-1-M 3F11 & 9-2-L387 2-1-L8 & 4C4

Monoclonal Antibodies




FIG. I

LOS Locus




FIG. 2A

1gtA

MQPLVSVLICAYNVEKYFAQSLAAVWNQTLRNLDILIVDDGSTDGTЛАIA
KDFQKRDSRIKILAQAQNGLIPSLNIGLDELAKGGGGEYIARTDADD
IASPGWIEKIVGEMEKDRSIIIAMGAWLEVLSEEKDGNRLARHHKHGKIWK
KPTRHEDIAAFFPPFGNPIHNNNTMIMRRSVIDGGLRYDTERDWAEDYQFWY
DVSKLGRLLAYYPEALKVYRQLHANQVSSKHSWRQHEIAQGIQKTARNDFLQ
SMGFKTRFDSLEYRQTKAAAYELPEKDLPEEDFERARRFLYQCFKRTDTP
PSGAWLDFAADGRMRRLFTRLQYFGILYRLLIKNRROQARSDSAQEIQI

FIG. 2B

1gtB

MQNHV1SLASAAERRAHIATFGSRGIPFQFFDALMPSERLERAMAELVP
GLSAHPYLSGVEKACFMSHAVLWEQALDEGVPPYIAWFEDDVLLGEQAQF
LAEDTWLQERFDPDSAFVVRLETMFMHVLTSPSGVADYGGRAFPPLLESEH
CGTAGY11SRKAMRFFLDRFAVLPPERLHPVDLMMFGNPDDREGMPVCQL
NPALCAQELHYAKFHDQNSALGSЛИEHDRRLNRKQQWRDSPANTFKHRLI
RALTKIGREREKRRQRREQLIGKIIIVPFQ

FIG. 2C

1gtC

M DIVFAADDNYAAYLCVAAKSVEAAHPDTEIRFHVL DAGI SEE NRAAVAA
NL RG GGNIRFIDVNPDFFAGFP LNIRHISITTYARLKLGEYIADCDKVL Y
LD TD VL VRD GLKPLWDTLGGN WVGACIDL FVERQEGYKQKIGMADGEYY
FN AGVLLINLK KWR RHDIFKMSCEWVEQYKDV M QYD QDI L NGL FKG GVC
YAN SRFNF MPT NYAFMANGFASRHTDPL YLDRTNTAMPVAVSHYCGSAKP
WH RDCTVWGAERFTELAGSLTTVPEEWRGKLA VPPPTKCM LQRW RKKL S AR
FLRK IY

FIG. 2D

1gtD

MQPLVSVLICAYNAEKYFAQSLAAVVGOTWRNLDDGSTDGTPAIA
RHFQEQDGRIIIISNPRNLGFIASLNIGLDELAKGSGGEYIARTDADDIA
SPGWIEKIVGEMEKDRSIIAMGAWLEVLSSEENNKSVLAAIARNGAIWDKP
TRHEDIVAVFPFGNPIHNNNTMRRSVIDGGRLRFDPAYIHAEDYKFHYEA
GKLGRLAYYPEALVKYRFHQDQTSSKYNLQQRRTAWKIKEEIRAGYWKAA
GIAVGADCLNYGLLKSTAYALYEKALSGQDIGCLRLFLYEFYFLSLEYSY
TDLDFLTDRVMRKLFAAPQYRKILKKMLRPWKYRSY

FIG.2E

1gtE

MQNHVISLASAAERRAHIADTFGSRGIPFQFFDALMPSERLEQAMAELVP
GLSAHPYLSGVEKACFMASHAVLWEQALDEGLPYIAWFEDDVLLGEgaeQF
LAEDTWLEERFDKDSAFIVRLETMFAKVIVRPDKVLNYENRSFPLLESEH
CCTAGYIISREAMRFFLDRFAVLPPERIKAVDLMMFYYFFDKEGMPVVQV
SPALCTQELHYAKFLSQNSMLGSDSLKDREQGRRHRRSLKWMFDLKRALG
KFGREKKRMRQRQAELEKVIYGRRVILFK

FIG. 2F

1 CTGCAGGCC TCGCCGTATT CAAACAACTG CCCGAAGCCC CCCGGCTCGC CGCCGCCAAC
 61 AAACCGCTGC AAAACCTGCT GAAAAAAGCC GATGCCGCGT TGGCGAAGT CAATGAAAGC
 121 CTGCTGCAAC AGGACGAAGA AAAAGCCCTG TACGCTGCCG CGCAAGGTTT GCAGGCCAAA
 181 ATTGCCGCG CCGTCGCCGA AGGCAATTTC CGAACCCGCCT TGTCCGAACT GGCTTCCGTC
 241 AAGCCGAGG TTGATGCCTT CTTCGACGGC GTGATGGTGA TGGCGGAAGA TGCCGCCGTA
 301 AACAAAAACC GCCTGAACCT GCTGAACCGC TTGGCAGAGC AGATGAACGC GGTGGCCGAC
 361 ATCGCGCTTT TGGGGAGATA ACCGGTTGTAC AGTCCAAATG CCTGCTGAAG CCTTCAGGGC
 421 GCATCAAATT ATCGGGAGAG TAAATTGCAG CCTTTAGTCA GCGTATTGAT TTGGCCCTAC
 481 AACGTAGAAA AATATTTTGC CCAATCATTAA GCCGCCGTG TGATTCAGAC TTGGCCGCAAC
 541 TTGGATATT TGATTGTCGA TGACGGCTCG ACAGACGGCA CACTTGCAT TGCCAAGGAT
 601 TTCAAAAGC GGGACAGGCC TATCAAATC CTTGCACAAG CTCAAAATTIC CGGCCTGATT
 661 CCCTCTTAA ACATCGGGCT GGACGAAATTG GCAAAGTCGG GGGGGGGGG GGGGAAATAT
 721 ATTGCCGCA CCGATGCCGA CGATATTGCC TCCCCCGGCT GGATTGAGAA AATCGTGGC
 781 GAGATGGAAA AAGACCCGAG CATCATGGCG ATGGGGGGGT GGCTGGAAGT TTTGTCGGAA
 841 GAAAGGAGG GCAACCGGGCT GGCGGGCAC CACAAACACG GCAAAATTTG GAAAAGCCG

FIG. 2G

901	ACCCGGACC AAGACATCGC CGCCCTTTTC CCTTCCGCA ACCCCATACA CAACAAACAG
961	ATGATTATGC GGGCAGCGT CATTGACGGC GGTTCGCGTT ACGACACCGA GCGGGATTGG
1021	GCGGAAGATT ACCAATTGGT GTACGATGTC AGCAAATTGG GCAGGCTGGC TTATTATCCC
1081	GAAGCCTTGG TCAAATACCG CCTTCACGCC AATCAGGTTT CATCCAAACA CAGCGTCCGC
1141	CAACACGAAA TCGGCCAAGG CATCCAAAAC ACCGCCAGAA ACGATTTTT GCAGTCTATG
1201	GGTTTAAAC CCCGGTTCGA CAGCCTAGAA TACCGCCAA CAAAGCAGC GGGGTATGAA
1261	CTGCCGGAGA AGGATTGCC GGAAAGAAGAT TTTGAACGGC CCCGCCGTT TTTGTACCAA
1321	TGCTTCAAAC GGACGGACAC GCCGCCCTCC GGCGCGTGGC TGGATTTCGC GGCAGACGGC
1381	AGGATGAGGC GGCTGTTAC CTTGAGGCAA TACTTCGGCA TTTTGTAACCG GCTGATTAAC
1441	AACGGCCGGC AGGGCGGTG GGATTGGCA GGGAAAGAAC AGGAGATTAA ATGCAAACCC
1501	ACGTTATCAG CTTGGCTTCC GCCGAGAAC GCAGGGGGCA CATTGCCCA ACCTTGGCA
1561	GTCGGGGCAT CCCGGTCCAG TTTTCGACG CACTGATGCC GTCTGAAAGG CTGGAACGGG
1621	CAATGGCGGA ACTCGTCCCC GGCTTGTGG CGCACCCCTA TTTGAGCGGA GTGGAAAAAG
1681	CCTGCTTTAT GAGCCACGCC GTATTGTGG AACAGGCATT GGACGAAGGC GTACCGTATA

1741 TCGCGTATT TGAAAGATGAT GTCTTAAC TCG GCGAAGGCC GGAGCAGTT CTTGCCGAAG
 1801 ATACTGGCT GCAAGAACGC TTTGACCCCG ATTCCGCCCT TGTGTCGCC TTGGAAACGA
 1861 TGTATGGCA CGTCCTGACC TCGCCCTCCG GCGTGGCGGA CTACGGCGGG CGGCCCTTC
 1921 CGCTTTGGA AAGCGAACAC TGCGGGACGG CGGGCTATAT TATTCCCCGA AAGGCCATGC
 1981 GTTTTCTT GGACAGGTTT GCCGTTTGC CGCCCGAACG CCTGCACCCCT GTCGATTGA
 2041 TGATGTCGG CAACCCGTGAC GACAGGGAAG GAATGCCGGT TTGCCAGCTC AATCCCGCT
 2101 TGTGCCCCA AGAGCTGCAT TATGCCAAGT TTCAACGACCA AAACAGCGCA TTGGCAGCC
 2161 TGATCGAAC A TGACCGCCGC CTGAACCGCA AACAGCAATG GCGCGATTCC CCCGCAAACA
 2221 CATTCAAACA CCGCCTGATC CGGCCCTGA CAAAATCGG CAGGAAAGG GAAAAACGCC
 2281 GGCAGGGCG CGAACAGTTA ATCGGCAAGA TTATTGTGCC TTTCCAATAA AAGGAGAAA
 2341 GATGGACATC GTATTTCGG CAGACGACAA CTATGCCGC TACCTTTCGC TTGGGGCAA
 2401 AAGCGTGGAA GCGGCCCATC CCGATA CGGAA AATCAGGTTT CACGTCTCG ATGCCGGCAT
 2461 CAGTGAGGAA AACCGGGCG CGGTTGCCGC CAAATTGCGGC GGGGGGGTA ATATCCGCTT
 2521 TATAGACGTA AACCCCGAAG ATTCGCCGG CTTCCCTTA AACATCAGGC ACATTTCCAT
 2581 TACGACTTAT GCCGCCCTGA AATTGGCGA ATACATTGCC GATTGCCGACA AAGTCCGTGA

FIG. 21

2641	TCTGGATAAG	GACCGTATTGG	TCAGGGACGG	CCTGAAGCCC	TTATGGGATA	CCGATTGGG
2701	CGGTAACTGG	GTCCGGCGGT	GCATCGATT	GTTTGTGCAA	AGGCAGGAAG	GATACAAACA
2761	AAAATCGGT	ATGGCGGACG	GAGAAATTAA	TTTCAATGCC	GGCGTATTGC	TGATCAACCT
2821	GAAGAAGTGG	CGGGGGCACG	ATATTTCAA	AATGTCCTGC	GAATGGGTGG	AACAATACAA
2881	GGACGTGATG	CAATATCAGG	ATCAGGACAT	TTTGAACCGGG	CTGTTTAAG	GCGGGGTGTG
2941	TTATGGAAAC	AGCCGGTTCA	ACTTITATGCC	GACCAATTAT	GCCTTTATGG	CGAACGGGTT
3001	TGCGTCCCCG	CATAACCGACC	CGCTTTACCT	CGACCGTACC	AATACGGGA	TGCCCCGTGCG
3061	CGTCAGCCAT	TATTGGGGCT	CGGCAAAGCC	GTGGCACAGG	GACTGCACCG	TTTGGGGTGC
3121	GGAAACGTTTC	ACAGAGTTGG	CGGGCAGCCT	GACGACCGTT	CCC6AAGAAT	GGGGCGGCAA
3181	ACTTGCCGTC	CCGGCGACAA	AGTGTATGCT	TCAAAGATGG	CGCAAAAGC	TGTCTGCCAG
3241	ATTCTTACGC	AAGATTATT	GACGGGGCAG	GCCGCTGAA	GCCCTCAGAC	GGCATCGGAC
3301	GTATCGGAA	GGGAGAAACGG	ATTGAGCCCT	TTAGTCAGCG	TATTGATTG	CGCCTACAC
3361	GCAGAAAAAT	ATTTTGCCCA	ATCATTGGCC	GGCGTAGTGG	GGCAGACTTG	GGCCAACTTG
3421	GATATTGGA	TTGTCGATGA	CGGCTCGACG	GACGGCACGC	CCGCCATTGC	CCGGCATTTC
3481	CAAGAACAGG	ACGGCAGGAT	CAGGATAATT	TCCAATCCCC	GCAATTTGGG	CTTTATCGCC

FIG. 2J

3541 TCTTTAAACA TCGGGCTGGA CGAATTGGCA AAGTCGGGG GGGGGAAATA TATTGGCCGC
 3601 ACCGATGCCG ACGATATTGC CTCCCCGGC TGGATTGAGA AAATCGTGGG CGAGATGGAA
 3661 AAAGACCGCA GCATCATTGC GATGGGGCGG TGGTTGGAAAG TTTTGTGGAA AGAAAACAAAT
 3721 AAAAGCGTGC TTGCGGCCAT TGCCCGAAC GGCGCAATT GGACAAACC GACCCGGCAT
 3781 GAAGACATTG TCGCCGTTT CCCTTTGGC AACCCCATAC ACAACAACAC GATGATTATG
 3841 AGGGCAGGG TCATTGACGG CGGTTTGGG TTGCGATCCAG CCTTATATCCA CGCCGAAGAC
 3901 TATAAGTTT GGTACGAAGC CGGCAAACGT GGCAAGGCTGG CTTATTATCC CGAAGCCTTG
 3961 GTCAAATACC GCTTCCATCA AGACCAGACT TCTTCCAAAT ACAACCTGCA ACAGGGCAGG
 4021 ACGGGCTGGA AAATCAAAGA AGAAATCAGG GCGGGGTATT GGAAGGGCGC AGGCATAGCC
 4081 GTCGGGGCG ACTGCTGAA TTACGGGCTT TTGAAATCAA CGGCATATGCA GTTGTACGAA
 4141 AAAGCCTTGT CCGGACAGGA TATCGGATGC CTCCGGCTGT TCCCTGTACGA ATATTTCTTG
 4201 TCGTTGGAAA AGTATTCTT GACCGATTG CTGGATTCT TGACAGACCG CGTGATGAGG
 4261 AAGCTGTTG CCGCACCGCA ATATAGAAA ATCCCTGAAA AAATGTTACG CCCTTGGAAA
 4321 TACCGCAGCT ATTGAAACCG AACAGGATAA ATCATGCAA ACCACGTTAT CAGCTTGGCT
 4381 TCCGGCGAG AGCGCAGGGC GCACATTGCC GATAACCTTCG GCAGTCGGG CATCCCGTTC

FIG. 2K

4441	CAGTTTTTCG	ACGGCACTGAT	GCCGTCTGAA	AGGCTGGAAC	AGGGATGGC	GGAACTCGTC
4501	CCCGGCCTGT	CGGGCACCC	CTATTTGAGC	GGAGTGGAAA	AAGCCTGCTT	TATGAGGCCAC
4561	GCCGTATTGT	GGGAACAGGC	GTTGGATGAA	GGTCTGCCGT	ATATGCCGT	ATTGAGGAC
4621	GACGGTTTAC	TCGGCGAAGG	CGCGGAGCAG	TTCCCTGCCG	AAGATACTTG	GTIGGAAGAG
4681	CGTTTGACA	AGGATTCCGC	CTTTATCGTC	CGTTGGAAA	CGATGTTGC	GAAAGTTATT
4741	GTCAGACCGG	ATAAAGTCCT	GAATTATGAA	AACCGGTCAT	TTCCCTTGC	GGAGAGCGAA
4801	CATTGTTGGAA	CGGCTGGCTA	TATCATTTCG	CGTAGGGCGA	TGCCGGTTTT	CTTGGACAGG
4861	TTTGCCTTT	TGCCGCCAGA	GCGGATTAAA	GCGGTAGATT	TGATGATGTT	TACTTATTTC
4921	TTTGATAAGG	AGGGGATGCC	TGTTTATCAG	GTAGTCCCG	CCTTAATGAC	CCAAGAATTG
4981	CATTATGCCA	AGTTTCTCAG	TCAAAACAGT	ATGTTGGGTAA	GCGAATTGGAA	AAAAGATAAGG
5041	GAACAAGGAA	GAAGACACCG	CCGTTCGTTG	AAGGTGATGT	TTGACTTGA	GGGTGCTTTG
5101	GGTAAATTCC	GTAGGGAAA	GAAGAAAAGA	ATGGAGCGTC	AAAGGCAGGC	GGAGCTTGAG
5161	AAAGTTTACG	GCAGGGGGGT	CATATTGTTTC	AAATAGTTTG	TGTAATAT	AGGGGATTA
5221	AATCAGAAAT	GGACACACTG	TCATTCCCAG	GCAGGGGGAA	ATCTAGGTCT	TTAAACTTCG
5281	GTTTTTTCG	ATAAATTCTT	GCCGCATTAA	AATTCCAGAT	TCCCGCTTTTC	GCGGGGATGA

FIG. 2L

5341 CGGGGGGG ATTGTTGCTT TTTCCGATA AATCCCCGT GTT TTTTCATCT GCTAGGTAAA
5401 ATCGCCCCAA AGCGTCTGCA TCGGGCGAT GGGGGCGAGT GGGGGGGTTT CTGTCGTAAC
5461 AATCGTTTT CCGAAGTGTAA CGGCCTGAAA GCCGGCTTCA AATGCCCTGT GTTCTTCCTG
5521 TTCTGTCCAG CGGCCTTCGG GCCCGACCAT AAAGACCGATT GCGCCGGACG GGTGGGGAT
5581 GTCGCCGAGT TTGCAAGGCC GGTGTATGCT CATAATCAGC TTGGTGTTTT CAGACGGCAT
5641 TTGTCGAGT GCTTCACGGT AGCCGATGAT GGGCAGTAGC GGGGAACGG TGTTCCTGCC
5701 GCTTTGTTCG CACGGGAGA TGACGATTTC CTGCCAGCGT GCAGGGCGTT TGGGGGGCG
5761 TTCTCGTCC AGGGGGACGA TGCAAGCGTT GCTGATGACG GGCTGTATGG CGGTTACGCC
5821 GAGTTCGAGG CTTTTTGCA GGGTGAATC CATGGGATC

FIG. 2M

Comparison of 1gtA and 1gtD

1gtA	1	LQPLVSVLICAYNVEKYFAQSLAAVVNQTWVNLDILIVDDGSTDGTLAIA	50
1gtD	1	LQPLVSVLICAYNVEKYFAQSLAAVVGQTWVNLDILIVDDGSTDGTPAIA	50
1gtA	51	KDFQKRSRIKILAQAQNGLIPSLNIGLDELAKSGGGGYEIARTDADD	100
1gtD	51	RHFQEQQDGRIRIISNPRNLGFIAISLNIGLDELAKS..GGGEYIARTDADD	98
1gtA	101	IASP GWIEKIVGEMEKDRSIIIAMGAWLEVLSEEKDGNRLARHHKHGKIWK	150
1gtD	99	IASP GWIEKIVGEMEKDRSIIIAMGAWLEVLSEEENIKSVLAAAIARGAIWD	148
1gtA	151	KPTRHEDIAAFFPFGNP IHNNNTMIMRRSVIDGGLRYDTERDWAEDYQFWY	200
1gtD	149	KPTRHEDIVAVFPFGNP IHNNNTMIMRRSVIDGGLRFDPAYIHAEDYKFWY	198

FIG. 3A

1gtA 201 DVSKLGRLLAYYPEALVKYRILHANQVSSKHSVRQHEIAQGIIQKTARNDFLQ 250
:::
:::
:::
:::
:::
:::
1gtD 199 EAGKLGRLLAYYPEALVKYRFHQDQTSSKYNLQQRRRTAWKIKEEIRAGYWK 248

1gtA 251 SMGFKTRFDSLEYRQTKAAAYELPEKDLPEEDFERARRFLYQCFKRTDTP 300
:::
:::
:::
:::
:::
:::
1gtD 249 AAGIAVGADCLNYGLLKSTAYALYEKALSQGDIGCRLFLYFYELSLEKY 298

1gtA 301 PSGAWILDFAADGRMRRLFTLRQYFGILYRLIKNRR 335

1gtD 299 SLTDLLDFLTDRVMRKLF AAPQYRKILKKMLRPWK 333

Comparison of 1gtB and 1gtE

1gtB	1	MQNHWVISLASAAERRAHIADTFGSRGIPFQFFDALMPSERLEQAMAEELVLP	50
1gtE	1	MQNHWVISLASAAERRAHIADTFGSRGIPFQFFDALMPSERLEQAMAEELVLP	50
1gtB	51	GLSAHLYLSGVEKACFMSHAVLWEQALDEGLPYIAVFEDDVLLGEGAEQF	100
1gtE	51	GLSAHPLSGVEKACFMSHAVLWEQALDEGLPYIAVFEDDVLLGEGAEQF	100
1gtB	101	LAEDTWLQERFDPSAFVVRLETMFMHYLTTSPSGVADYGRAFPILLESEH	150
1gtE	101	LAEDTWLEERFDKDSAFIVRLETMFAKVIVRPDKVLNYENRSFPLLESEH	150
1gtB	151	CGTAGYIISRKAMRFFLDRFAVLPPERLHPVDLMMFGNPPDDREGMPVCQL	200
1gtE	151	CGTAGYIISREAMRFFLDRFAVLPPERIKAVDLMFTYFFDKEGMPVYQV	200

1gtB 201 NPALCAQELHYAKFHDQNSALGSLIEHDRRLNRKQQRDDSPANTFKHRLI 250
1gtE 201 SPALCCTQELHYAKFLSQNSMILGSDELEKD . . . REQGRRHRRSLKVMFDLK 246

1gtB 251 RALT KIGREREKRRKRR . . . EQTICKITIVPFQ 279
1gtE 247 RALGKFGREKKRMERQRQAELEKVYGRRVILFK 280

FIG. 4B

Comparison of rfaI and lgtC

rfaI	29	LDIAYGTDKNFLGGISIASILKYNEGSRLCFHIFTDYFGDDDKYFDA	78
1gtc	1	M DIVFAADDNYAAYLCVAAKSVEAAHPDTEIRFHVL DAG ISEENRAAVAA	50
rfaI	79	LALQYKTRIKIYLINGDRRLRSLP . STKNWTHAIYFRFVIADYFINKAPKV	127
1gtc	51	. NLRGCCNIRFIDVNPEDFAGFP LNIRHISITTYARLKLGEY . IADCDKV	98
rfaI	128	LYLDADIICQGTIEPLINFSFPDDKVKAMVV . . TEGQADWMEKRAHS LGV	174
1gtc	99	LYLDTDVLVRDGGLKPLWDTDLGGNWVGACIDL FVERQEYKQK . . IGM	144
rfaI	175	AGIAKGYFNSGFLLIINTAQWAAQQVSARAIAMLNEPEIIKKKITHPDQDW L	224
1gtc	145	AD . GEYYFNAGVLLINLKWKRRHDIFKMSCEWVEQYKDVMQ . . YQDQDIL	191

FIG. 5A

rfaI 225 NMLLADKLI^FADIKYNTQFSLNYQLKESFINPV^TNDTIFI..... 264
1gtC 192 NGLFKGGV^CYANSRFNF.MPTNYAFMANGFASRHTDPLYLDRTNTAMPVA 240

rfaI 265 ..HYIGPTKPWHDWADYPVSQAFMEA^KNASPWKNTALLKPNNSNQLRYS 312
1gtC 241 VSHYCGSAK^PWH..RDCTVWGAERFTELAGSL..TVVPEEWRGKLAVPP 285

rfaI 313 AKHMLKKHRYLKGF^SNYLFYFI 334
1gtC 286 T^KCML..QRWRKKLSARFLRKI 305

FIG. 5B

Deletions in LOS Locus




FIG. 6

WO 96/10086

22/23

PCT/US/5/12317



FIG. 7




FIG. 8

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/12317

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/54 C12N9/10 C12N5/10 C12P19/18 // (C12N9/10, C12R1:36)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C07K C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	METHODS ENZYMOL., 1994, 235/- (253-285), USA, ROSENTHAL R.S. ET AL 'Isolation of peptidoglycan and soluble peptidoglycan fragments' see the whole document ---	1, 16, 22
A	MOL. MICROBIOL., 1994, 14/4 (609-618), UNITED KINGDOM, ZHOU D. ET AL 'Lipoooligosaccharide biosynthesis in Neisseria gonorrhoeae: Cloning, identification and characterization of the alpha1,5 heptosyltransferase I gene (rfaC)' see the whole document ---	1, 13-16, 22 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- 'A' document member of the same patent family

Date of the actual completion of the international search

25 January 1996

Date of mailing of the international search report

29. 02. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+ 31-70) 340-3016

Authorized officer

Gurdjian, D

INTERNATIONAL SEARCH REPORT

Inter. Application No
PCT/US 95/12317

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EUROPEAN JOURNAL OF BIOCHEMISTRY, 1983, STEPHENS PE ET AL 'NUCLEOTIDE-SEQUENCE OF THE LIPOAMIDE DEHYDROGENASE GENE OF ESCHERICHIA-COLI-K12' see the whole document ---	1,13-16, 22
P,X	J. EXP. MED. (1994), 180(6), 2181-90 CODEN: JEMEAV; ISSN: 0022-1007, GOTTSCHLICH, EMIL C. 'Genetic locus for the biosynthesis of the variable portion of Neisseria gonorrhoeae lipooligosaccharide' see the whole document ---	1-33
A	INFECTION AND IMMUNITY, vol. 29, no. 3, 1980 pages 914-925, SINHA R.K. ET AL. 'Release of soluble peptidoglycan from growing Gonococci: demonstration of anhydro-muramyl-containing fragment' see the whole document ---	16
A	MOLECULAR MICROBIOLOGY, vol. 5, no. 5, 1991 pages 1113-1124, COPE L.D. ET AL. 'Molecular cloning of a gene involved in lipooligosaccharide biosynthesis and virulence expression by Haemophilus influenzae type B.' see the whole document ---	13,14
A	EP,A,D 474 313 (INGENIERIA GENETICA Y BIOTECNO) 11 March 1992 see claims 1,11,13 ---	13-16
A	EP,A,D 585 109 (SUNTORY LTD ;TANIGUCHI NAOYUKI (JP)) 2 March 1994 see claims 1-9 -----	13-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PC1/US 95/12317

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-0474313	11-03-92	AU-B-	657487	16-03-95
		AU-B-	8368391	12-03-92
		CA-A-	2050749	08-03-92
		JP-A-	6169779	21-06-94
		US-A-	5286484	15-02-94
-----	-----	-----	-----	-----
EP-A-0585109	02-03-94	JP-A-	6197756	19-07-94
-----	-----	-----	-----	-----

THIS PAGE BLANK (USPTO)